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CHAPTER I 
 
INTRODUCTION 
 
Overview 
 Appropriate response to a variety of intra- and extracellular stress signaling 
molecules is critical for maintenance of proper cellular function.  As such, there exist 
many signaling pathways in the cell that are capable of sensing and responding to 
signals of varying chemotypes.  A unifying feature of these pathways is the ability of 
sensor proteins to translate a non-specific chemical signal into a specific biological 
response.  This is in direct contrast to receptor-ligand or antibody-antigen based 
signaling which relies on a specific signal to generate a specific response.  The end 
result of signaling through stress response pathways typically is one of two phenotypes: 
adaptive stress response or programmed cell death.  Understanding how the master 
regulatory proteins for these pathways sense chemical stress and are regulated is 
therefore of great interest and could potentially have an important impact on human 
health.   
Apoptosis signal-regulating kinase 1 (ASK1 or MAP3K5) is one such regulatory 
switch that integrates a wide array of stress signals and transduces them into activation 
of the mitogen-activated protein kinase (MAPK) signaling cascade.  Upon activation by 
these stimuli, ASK1 phosphorylates downstream kinases and initiates the P38 and JNK 
signaling cascades that ultimately result in apoptosis if the stress signal is severe 
enough.  Because of its role as a key regulator of two important MAPK pathways, ASK1 
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is tightly regulated by both phosphorylation and protein-protein interactions.  
Understanding how these regulatory mechanisms function in response to diverse stress 
stimuli is important for predicting how ASK1 will function in various disease states where 
these stressors are present.  Until now, most of the mechanistic work in the ASK1 field 
was performed using H2O2 as the activating stress molecule to trigger ASK1 signaling.  
H2O2 is a valid and interesting second messenger that plays a role in stress signaling in 
many contexts, but it is only one of many known ASK1 activating molecules.  A deeper 
understanding of how ASK1 is regulated in response to other stressors of diverse 
chemotypes is needed and may provide valuable insight into how stress sensing 
proteins as a whole are able to transduce non-specific chemical signals into specific 
biological responses. 
 The work presented in this dissertation examines the regulatory mechanisms of 
ASK1 in response to 4-hydroxy-2-nonenal (HNE), an endogenously produced end 
product of lipid peroxidation that can activate the ASK1 MAPK pathway.  I hypothesize 
that ASK1 or its regulatory protein partners are chemically modified by electrophiles 
(represented by HNE), resulting in ASK1 pathway activation and a change in the 
regulatory mechanisms of ASK1.  These regulatory mechanism changes could manifest 
as a change in the protein-protein interactions of ASK1 and as a change in the 
phosphorylation pattern on ASK1.  The following chapters present a series of studies 
using mass spectrometry to examine the dynamic changes in protein-protein 
interactions and phosphorylation for ASK1 as a result of HNE treatment.  The remainder 
of chapter I will examine the importance of oxidative stress, discuss what is known 
about ASK1 and its regulation, introduce the mass spectrometry concepts that will be 
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used in the later chapters, and provide a rationale for the studies discussed in chapters 
2 and 3. 
 
Oxidative Stress 
 Oxidative stress is acknowledged as an important component of many disease 
states, including cardiovascular disease, neurological disease, liver disease, and 
diabetes, and plays a principal role in disease processes involving inflammation (1-10).  
One interesting area of human health where oxidative stress plays a role is in 
neurodegenerative diseases, due to the large amount of oxygen, lipids, and reactive 
metals present in the brain (2, 3).  Whether this oxidative stress is causative or 
symptomatic of neurodegeneration is unknown; but in either case, oxidative stress 
appears to be an important part of these disease states.  Both Alzheimer’s disease and 
Parkinson’s disease are characterized by high concentrations of oxidized cellular 
components (proteins, lipids, and DNA) and reactive oxygen species (ROS) levels (11, 
12).  ROS exist in many forms in the cellular environment; commonly observed species 
include the superoxide anion, hydrogen peroxide (H2O2), and hydroxyl radical (13).  Of 
these three, H2O2 is the least reactive and thus most diffusible molecule and has been 
recognized as a second messenger in many signaling pathways (14).  Many of the 
endogenously generated ROS are created in the mitochondria through the process of 
oxidative respiration and, as such, these highly reactive species are present in areas 
with high lipid content (organelle membranes) which leads to the creation of reactive 
lipid electrophiles like HNE (15).   
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Lipid electrophiles are created through a series of radical-mediated 
polyunsaturated fatty acid peroxidation reactions that can propagate beyond the initial 
site of damage to result in the generation of many molecules of reactive peroxidation 
products for each molecule of initiating ROS (15, 16).  One of the most well-studied end 
products of this chain reaction is the ,-unsaturated aldehyde HNE, which is 
considered the prototype for the whole class of lipid electrophiles (17, 18).  HNE can 
diffuse far from the site of creation and is capable of damaging DNA and proteins (15, 
17).  The protein damage is typically in the form of Michael adducts on nucleophilic 
amino acids (Fig. I-1).  The most commonly adducted sites in proteins are cysteine 
residues, but histidine and lysine adducts also occur (19).  HNE can also produce Schiff 
base adducts with lysine residues, giving this molecule the ability to crosslink proteins 
(20, 21).  Identification of the exact sites of HNE adduction in a protein can be 
accomplished via mass spectrometry techniques (22-25), which can greatly aid in 
understanding the functional consequences of this adduction.    
It is interesting to note that cysteine residues are the recipients of most of the 
oxidative and alkylation damage to proteins.  Initially, it was believed that the majority of 
this damage was non-specific, but recently it has become clear that the modification of 
proteins by reactive species is a highly specific phenomenon that controls many 
processes in the cell (26).  The interplay between direct oxidation of proteins and the 
generation of reactive lipid electrophiles by ROS is even more interesting when one 
takes into account that the damage done to proteins is generally readily reversible in the 
former case and less so in the latter (16, 26).  Understanding how a sensor protein like 
ASK1 is capable of responding to both types of stress is of considerable interest.  
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Figure I-1.  HNE Michael adduct on cysteine residue. 
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Apoptosis Signal-regulating Kinase 1 
Apoptosis Signal-regulating Kinase 1 is a mitogen-activated protein kinase 
(MAPK) kinase kinase (MAP3K) which acts as a key stress sensor for the cell upstream 
of the P38 and JNK pathways (27).  It was first described by Ichijo et. al. in 1997 as a 
154 kDa MAP3K protein that was capable of directly phosphorylating MKK3, MKK4, and 
MKK6 and thereby activating the P38 and JNK pathways in response to treatment of 
cells with tumor necrosis factor alpha (TNF.   
 
ASK1 Protein Structure 
ASK1 consists of three large domains: an N-terminal coiled-coil domain, a 
serine/threonine kinase domain, and a C-terminal coiled-coil domain (28).  In addition, 
ASK1 contains several smaller domains with specific binding recognition sequences, 
including a 14-3-3 binding motif and a deubiquitinase binding motif (Fig. I-2) (28, 29).   
ASK1 exists as a homodimer that is joined through both its c-terminal coiled-coil domain 
and its kinase domain and interacts with a number of other proteins, potentially in a 
large complex termed the ASK1 signalosome (28, 30, 31). 
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Figure I-2. ASK1 domain structure with key phosphorylations highlighted.  Red 
circles indicate inactivating phosphosites while the green circle indicates the activating 
one. NCC/CCC = N/C-terminal coiled-coil domain. 
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ASK1 Evolutionary Conservation  
The role of ASK1 in the MAPK pathway appears to be evolutionarily conserved 
as the Drosophila analogue (DASK1) and the C. elegans analogue (NSY-1) both 
activate their respective P38 and JNK pathways (32, 33).  Additionally, the broad 
structural features of ASK are similar among these three organisms – the activation 
domain in particular is highly conserved (32).  ASK1 also shares a great deal of 
similarity with 14 other members of the homo sapiens MAP3K family members.  The 
kinase domain of ASK1 is fairly well conserved among all MAP3Ks, but especially when 
compared against ASK2 (80% similarity) and ASK3 (87% similarity) (34-36). 
 
Activation of the ASK1 MAPK pathway in response to stress 
 Activation of ASK1 by stress signals results in autophosphorylation of a critical 
threonine residue (T838) and subsequent phosphorylation of MAP2Ks in the P38 and 
JNK pathways – specifically, MKK3/6 and MKK4/7 (27, 32).  Upon phosphorylation by 
ASK1, the MAP2K proteins are activated and in turn can phosphorylate their MAPK 
targets: P38 and JNK(32).  The end result of this signaling pathway is either adaptive 
stress response or apoptosis, depending on the severity of the stress.  In the case of 
apoptosis, signaling through the ASK1 MAPK pathway results in release of cytochrome 
c from the mitochondria and activation of caspase 9 and caspase 3 in a canonical 
mitochondria-dependent apoptotic pathway (37). 
 Activation of ASK1 and subsequent apoptotic cell death can occur as a result of 
a number of stress insults.  ASK1 is known to be activated in response to both 
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endogenously- and exogenously-generated stress signals (Fig. I-3).  Endogenously, 
ASK1 is activated in response to oxidative stress, endoplasmic reticulum stress, calcium 
stress, and inflammatory signals (32, 38-41).  Additionally, many chemical species are 
known to activate ASK1, including methylmercury, 1,2-naphthoquinone, denbinobin, 
acetaminophen, troglitazone, 2,3,7,8-tetrachlorodibenzo-p-dioxin, acrolein, capsaicin, 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 6-hydroxydopamine, and paraquat (42-52).  
While many molecules are known to activate ASK1, two in particular (TNF and H2O2) 
have been used extensively to characterize the function of ASK1.   
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Figure  I-3.  ASK1 is activated in response to many different stressors. Reproduced 
with permission from Hayakawa et. al. Proc Jpn Acad Ser B Phys Biol Sci. 2012; 
88(8):434-453. 
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Activation of ASK1 by TNF 
TNF was the first stress signal defined as an ASK1 activator, as it was already 
known to activate the P38 and JNK pathways (27).  It was further noted that ASK1 is 
required for TNFmediated sustained activation of these two pathways via use of a 
mouse knockout model (53).  This experiment confirmed ASK1 as a TNF-responsive 
protein and localized the induction of that signal to the MAP3K level of the P38 and JNK 
pathways.  In another study, it was shown that TNF receptor-associated factor 2 
(TRAF2) is also required for ASK1 activation by TNF which suggested that, while 
TNF acted at the MAP3K level in the signaling pathway, it did not directly act on ASK1 
(54).   
Further evidence of the indirect action of TNF on ASK1 came about after the 
discovery of the ASK1-interacting protein thioredoxin (TRX).  TRX is a small (~12kDa) 
protein with a redox-active pair of Cys residues (Cys 32 and 35) that, upon oxidation, 
form a disulfide bond.  It is this bond formation that was believed to cause TRX to 
dissociate from ASK1, thereby relieving ASK1 of its inhibitory influence (38).  The link 
between the redox regulation of ASK1 and activation of ASK1 by TNF was first made 
by Liu et.al. who observed that TNF activation of this pathway was dependent on 
ASK1-TRAF2 association, which was in turn dependent on TRX-ASK1 dissociation (55).  
This study further noted that TNF production or overexpression of TRAF2 causes an 
increase in ROS levels within the cell, which would allow for oxidation of TRX and 
activation of ASK1 (55). 
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Activation of ASK1 by ROS and HNE 
 Because activation of ASK1 via TNF was redox-dependent, the focus in the 
literature shifted to using H2O2 to study ASK1 activation.  One of the first studies to 
focus on H2O2 as an activator of ASK1 used ROS scavengers to show that TNF-
mediated activation of ASK1 was likely redox-dependent (56).  As a consequence, the 
majority of the protein-protein interaction studies on ASK1 have been performed using 
H2O2 to stress the cell model systems.  These experiments will be described in the 
protein-protein interaction section below.   
Another known activator of ASK1 is HNE (57).  As discussed above, HNE is an 
electrophilic end product of lipid peroxidation that is capable of diffusing throughout the 
cell and causing damage to macromolecules like DNA and proteins (16, 17).  Adduction 
of proteins by HNE has been observed to alter intracellular signaling pathways 
(including activating the ASK1 pathway) and is therefore of considerable biological 
interest (16, 24, 57, 58).  Specifically, HNE has been shown to be involved in the NF-B 
and KEAP1/NRF2 pathways among others (58).  In the NF-B pathway, HNE was 
found to directly inhibit IB kinase (IKK) which is responsible for phosphorylating the 
NF-B inhibitory protein IB.  By inhibiting IKK, HNE blocks the translocation of 
NF-B to the nucleus and the subsequent gene regulation by this transcription factor 
(58, 59).   
The KEAP1/NRF2 pathway works by a similar mechanism to the NFkB pathway 
– NRF2 is a transcription factor that promotes transcription of anti-oxidant genes (the 
anti-oxidant response element).  NRF2 transactivation of its target genes is controlled 
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by KEAP1-mediated degradation of NRF2.  Upon oxidative or electrophilic modification 
of KEAP1 sensor cysteine residues by HNE and other chemicals, NRF2 is released 
from its complex with KEAP1, translocates to the nucleus, and promotes target gene 
expression (58).  It has been shown that HNE directly adducts KEAP1, which results in 
an increase in NRF2 target gene transcription and that decreased KEAP1 expression 
confers resistance to HNE stress (60-63). 
As mentioned above, HNE has also been shown to activate ASK1 and the 
downstream MAPK pathway in PC12 cells (57).  The mechanism of ASK1 activation by 
HNE was not examined in this study, but given the examples of HNE modulation of 
other pathways above, it is reasonable to hypothesize that the activation of ASK1 is 
accomplished through a similar means.  Thus, it is possible that direct covalent 
modification of ASK1 by HNE may be the activating step for HNE-mediated MAPK 
signaling.  In support of this hypothesis, we have shown that ASK1 can also be 
activated by HNE in HEK-293 cells and, furthermore, that ASK1 is covalently modified 
by HNE (see chapters II-III). 
 
Functional role and disease relevance of ASK1 
ASK1 has been most often studied for its role in apoptotic regulation and, as 
evidenced by their evolutionary conservation, the MAPK stress pathways that are 
controlled by ASK1 are quite important.  Dysregulation of the P38 and JNK pathways 
has been implicated in several disease states, including cancer, heart disease, 
diabetes, polyglutamine repeat disorders, Parkinson’s disease, Alzheimer’s disease, 
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multiple sclerosis, and amyotrophic lateral sclerosis (64-70).  As a key control step for 
the JNK and P38 MAPK pathways, ASK1 has been investigated in many of these 
disease contexts to see if the dysregulation of the pathway originated with a change in 
ASK1 signaling.  Conflicting roles have been reported for ASK1 in cancer depending on 
the cellular context.  Through an investigation of skin cancer in a murine model system, 
ASK1 was shown to work in concert with ASK2 to promote apoptosis of carcinogenic 
cells; however in the same study it was noted that in cells that had ASK2 knocked out, 
ASK1 promoted tumorigenesis (71).  In the context of gastric cancer however, the 
results were clearer - ASK1 acted as a tumor promoter in conjunction with the protein 
cyclin D1 and inhibition of ASK1 with a small molecule retarded tumor growth (72, 73). 
Despite the conflicting reports in the context of cancer, there has been more of 
an interest in the role of ASK1 in neurodegenerative diseases and in attempting to 
develop drugs to target ASK1 in this context (70, 74).  In the case of Alzheimer’s 
disease, ASK1 is believed to be activated in response to ROS caused by the buildup of 
amyloid beta plaques (75).  Similarly, ROS-induced activation of ASK1 was found to be 
important in Parkinson’s disease as well (50).   
In the case of Huntington’s disease, caused by expansion of polyglutamine 
repeats in key genes, ASK1 has been found to play a role in the subsequent neuronal 
cell death via endoplasmic reticulum (ER) stress activation of the JNK pathway that is 
abrogated in ASK1 knockout mice (41).  Another neurological condition symptomatically 
linked to ASK1 activation by ER stress is familial amyotrophic lateral sclerosis (76).  In 
this context, ER stress is caused by a mutant superoxide dismutase protein, which then 
results in ASK1 pathway activation and apoptotic cell death.  This cell death was 
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mitigated in an ASK1 knockout model system (76).  ASK1 is also believed to play a role 
in multiple sclerosis, whereby the inflammatory signaling pathways activate ASK1 (77).  
An ASK1 knockout mouse model of multiple sclerosis showed reduced cell death and 
neuroinflammation and an inhibitor of ASK1 applied to an ASK1 expressing multiple 
sclerosis model in vivo had a similar effect (77). 
 In addition to diseases where ASK1 signaling and subsequent MAPK pathway 
activation results in apoptosis and disease progression, ASK1 is also believed to play a 
role in the immune response to foreign pathogens (70, 78).  ASK1 has been reported to 
be important for the defensive macrophage apoptotic response to mycobacterium 
infection (79).  Additionally, ASK1 has been implicated as an activator in influenza virus-
mediated apoptosis of infected cells as a host defense mechanism (80).  This type of 
ASK1-regulated apoptotic antiviral response mechanism may be fairly ubiquitous, as it 
has also been demonstrated that the human immunodeficiency virus 1 (HIV-1) protein 
Nef inhibits the function of ASK1 to decrease apoptosis of infected cells (81).  
Interestingly, ASK1 has also been shown to interact with another HIV-1 protein called 
Vif and this interaction promotes the stabilization of another host protein called A3G 
which destroys viral RNA before it is reverse-transcribed (82).  Thus, it seems that 
ASK1 plays both a direct and indirect role in innate immune response. 
 The wide variety of human pathologies described above where the ASK1 MAPK 
pathway is believed to play a critical role highlight the importance of understanding the 
ASK1 system.  Better knowledge of the regulation of ASK1 and under what conditions it 
is activated could potentially reveal new therapeutic targets to ultimately improve human 
health.   
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Because of the key role that ASK1 plays in determining cell fate in response to a 
highly varied set of signals, careful regulation of its activity is extremely important.  This 
regulation is achieved through two interrelated mechanisms: phosphorylation and 
dynamic changes in protein-protein interactions.  Each of these will be discussed in 
detail below. 
 
ASK1 Phosphoregulation 
 Regulation of ASK1 function by differential phosphorylation is an important 
control mechanism employed by the cell.  ASK1 is a large protein and has 114 serine, 
77 threonine, and 40 tyrosine residues that could serve as potential regulatory sites.  In 
practice, however, only 5 phosphorylated sites have thus far been identified as 
important for regulation (Fig. I-2).  It is interesting to note that four of these are 
inhibitory, with only one phospho-residue serving an activating role (49). 
 The sole well-studied phospho-tyrosine residue in ASK1 is Tyr-718, which acts 
as a binding location for suppressor of cytokine signaling 1 (SOCS1).  This residue is 
phosphorylated by Janus Kinase 2 (JAK2) to allow SOCS1 to bind and promote the 
degradation of ASK1 through recruitment of ubiquitin ligase proteins (83, 84).  TNF 
treatment promotes a decrease in phosphorylation at this site, which is accomplished 
via the protein tyrosine phosphatase SHP2 (83, 84). 
 One of the most well-studied inactivating phosphorylations on ASK1 is on Ser-83.  
It was first noted that pro-survival kinase AKT could phosphorylate ASK1 at Ser-83 and 
decrease the kinase activity of ASK1 in response to H2O2 (85).  Later, PIM1 was also 
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identified as a kinase that can phosphorylate ASK1 at Ser-83 with a similar negative 
impact on ASK1 function (86).  These two kinases act in different biological contexts to 
phosphorylate the same residue on ASK1, thereby keeping tight control over the activity 
of ASK1 (86). 
 Similarly, ASK1 is phosphorylated on Ser-966 by 3-phosphoinositide-dependent 
protein kinase 1 (PDK1), which serves as a negative regulator of ASK1 by acting as a 
binding site for 14-3-3 proteins (87, 88).  Dephosphorylation of this site by protein 
phosphatase 2A (PP2A) results in decreased 14-3-3 binding to ASK1 and increased 
ASK1 activity (89, 90).  One last known inactivating phosphorylation on ASK1 is on Ser-
1033 which has been shown to be present on ASK1 and to correlate with decreased 
ASK1 activity (90).  However, unlike the other residues, no kinase or phosphatase is 
known for this site. 
 As the sole known activating phosphorylation on ASK1, Thr-838 has been 
thoroughly investigated and is often used as a surrogate marker for ASK1 activity.  This 
key phosphosite is autophosphorylated by N-terminal dimerization of ASK1 and possibly 
phosphorylated by ASK2 or another unidentified kinase (30, 36, 56).  Two different 
phosphatases have been identified as capable of removing the phosphorylation from 
Thr-838, which highlights the importance of fine control over this site.  The first 
phosphatase that targets Thr-838 was identified as protein phosphatase 5 (PPP5C), 
which was shown to act in response to ROS (91).  Recently, Cho et. al. reported that 
cell division cycle 25C (CDC25C) was also capable of dephosphorylating Thr-838 of 
ASK1 and that it could do so in a cell cycle-dependent fashion by inhibiting ASK1 
activity during interphase (92).  Interestingly, cells that were halted in mitosis showed an 
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increase in ASK1 activity and a decreased association between CDC25C and ASK1, 
suggesting that, in addition to stress response, ASK1 may play an important role in 
normal cell cycle events (92). 
In addition to pThr-838, two other threonine residues have been identified as 
potential autophosphorylation sites on ASK1.   Thr-813 and Thr-842 have been shown 
to become autophosphorylated when the kinase domain of the protein is expressed by 
itself and mutation of either of these residues to alanine resulted in a decrease in 
reporter gene activity in a cell model of ASK1-JNK signaling (28).  However, in an in 
vitro phosphorylation model, mutation of each threonine residue (813, 838, and 842) 
resulted in similar activity levels as the wild type protein, indicating that these residues 
may be more important for protein-protein interactions than for intrinsic kinase activity 
(28). 
 
ASK1 regulation by protein-protein interactions 
Signalosome hypothesis 
 Since ASK1 was first described, over 80 proteins have been reported as ASK1-
interacting proteins.  All of these proteins have been investigated for a positive or 
negative regulation on the function of ASK1 and, taken together, they form a highly 
nuanced regulatory mechanism that can exercise fine control over ASK1-mediated 
MAPK pathway signaling.  In almost every case, the ASK1-interacting proteins have 
been examined as part of a binary interaction with ASK1.  Thus, our understanding of 
 19 
the protein-protein regulatory mechanism for ASK1 is limited to how these protein pairs 
dynamically associate or dissociate in response to stress.   
However, in 2005 Noguchi et. al. performed a gel filtration experiment (Fig. I-4) in 
which they showed that ASK1 formed a constitutive high molecular mass complex that 
shifted to an even higher mass complex upon activation of ASK1 (93).  This observation 
led to the hypothesis that ASK1 is actually regulated by a large multiprotein complex 
that they named the ASK1 signalosome.  The exact membership of this proposed 
signalosome has never been investigated, but the potential members include all of the 
reported ASK1 interacting proteins.  These proteins will be discussed in detail below in 
the context of the binary interaction between each protein and ASK1, and are further 
summarized in Table 1 at the end of this chapter.  
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Figure I-4.  The ASK1 complex shifts to a higher molecular mass upon 
treatment with H2O2.  Reproduced with permission from Takuya Noguchi et 
al. J. Biol. Chem. 2005;280:37033-37040. 
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ASK1 and its related kinase ASK2 
 ASK2 is another MAP3K that shares a good deal of homology with ASK1 (~45% 
overall, ~80% in the kinase domain) and is also capable of activating the JNK and P38 
MAPK pathways (94).  While ASK1 has been the focus of a large research effort, the 
functional importance and regulation of ASK2 remains largely unknown.  A pair of 
studies determined that ASK2 exists in a heteromeric complex with ASK1 and that 
these two kinases may directly affect each other (36, 95).  One study found that ASK1 
stabilized ASK2 by inhibiting the degradation of ASK2 and that, in turn, ASK2 was 
capable of phosphorylating ASK1 and promoting its activity (36).  A second study also 
found that ASK2 supported and enhanced ASK1-mediated signaling (95).  Interestingly, 
while these studies above would indicate a positive regulatory role of ASK2, a later 
report indicated that ASK2 enhanced 14-3-3 binding to ASK1 which negatively regulates 
ASK1 (96).  However, in a mouse tumor model, ASK1 and ASK2 were observed to work 
cooperatively as tumor suppressors by triggering apoptosis, which would seem to 
support the idea of ASK2 as a positive regulator of ASK1 (71).  Given the conflicting 
reports discussed above, more study of the role that ASK2 plays in ASK1 regulation is 
needed.  Several other ASK1-interacting proteins also have conflicting roles reported in 
the literature (see below), thus it is possible that many of the protein-protein interactions 
that regulate ASK1 may possess varying roles depending on the stress and cellular 
context.   
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ASK1 regulation by protein turnover  
The first reported protein-protein interaction for ASK1 was with TRX and was 
described shortly after the function of ASK1 was elucidated (38).  The TRX-ASK1 
interaction was detected using a yeast two-hybrid strategy, and it was further 
demonstrated with a series of ASK1 deletion mutants that TRX bound with the N-
terminus of ASK1.  This study also showed that TRX had an inhibitory effect on the 
function of ASK1 and that this inhibition was dependent on the redox status of TRX (38).  
The end result of this study was the first model of ASK1 regulation, which has largely 
remained unchanged (Fig. I-5).  Later, it was shown that the repression of ASK1 activity 
by TRX was due to TRX blocking a homophilic interaction between the N-terminal 
regions of two ASK1 molecules (31).  In addition to this mechanism of inhibition, TRX is 
also capable of promoting ubiquitination of ASK1 as a means of controlling its activity 
(97). 
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Figure I-5.  Initial model of ASK1 
regulation by TRX.  Reproduced with 
permission from Saitoh et. al. The EMBO 
Journal. 1998; 2596-2606. 
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While TRX was the first protein reported to promote ubiquitination of ASK1, it is 
not the only one, as ubiquitination has been recognized to play an important role in 
ASK1 regulation.  Ubiquitination is a post-translational modification, whereby ubiquitin (a 
small protein made of 76 amino acids) is attached via its C-terminal glycine to another 
protein at the epsilon amino group of a lysine.  Additional ubiquitin molecules can be 
added to ubiquitin lysine residues to form polyubiquitin chains, which act as degradation 
signals and target the polyubiquitinated proteins to the proteasome for degradation (98).  
Ubiquitination (Fig. I-6) is a multi-step process that begins when an E1 enzyme (UBA1 
or UBA6 in humans) transfers a bound ubiquitin molecule to an E2 enzyme (there are 
more than 30 encoded in the human genome) (98, 99).  Once the ubiquitin is attached 
to the E2, it must be transferred to one of several hundred E3 enzymes prior to making 
the final transfer to the target substrate protein (99).   
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Figure I-6.  Ubiquitin pathway.  (A) Ubiquitin transfer mechanism.  (B) 
Hierarchical diagram of ubiquitin pathway.  Reproduced with permission 
from Pickart and Eddins, Biochimica et Biophysica Acta 1695 (2004) 55–
72. 
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Several proteins have been reported to function as E3s for ASK1 and facilitate 
degradation.  It remains unclear whether there are only certain contexts in which each 
of these proteins functions or if there is some other diversity of function that would 
explain the apparent redundancy of having multiple distinct E3 ligases.  Nonetheless, 
each of the proteins below has been demonstrated to function as an E3 and promote 
the degradation of ASK1.   
The first E3 reported for ASK1 was the protein C-terminus of heat shock protein 
70-interacting protein (STUB1, commonly known and referred to hereafter as CHIP).  
Overexpression of CHIP and reconstituted in vitro systems both demonstrated that 
CHIP has the ability to ubiquitinate ASK1 (100, 101).  Furthermore, this ubiquitination 
was increased in response to H2O2 treatment and decreased following CHIP knockdown 
(101).  As part of the CHIP-mediated degradation of ASK1, heat shock protein 70 
(HSPA1A and HSPA4, collectively referred to here as HSP-70) has been reported to 
bind to ASK1 and, together with CHIP, target ASK1 for proteasomal degradation (100).  
This function of HSP-70 as a co-E3 with CHIP expands upon an earlier report that 
identified HSP-70 as a negative regulator of ASK1 which interfered with the n-terminal 
dimerization of ASK1 (102). 
Cellular inhibitor of apoptosis protein 1 (BIRC2) was the next E3 identified for 
ASK1.  Evidence similar to that seen for CHIP was presented here, but in this case, 
TNF was the stressor used (103).  This could suggest that each type of stress 
activation has at least some unique protein-protein interactions.   
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Roquin-2 (RC3H2) was recently identified by the Ichijo group as a third E3 for 
ASK1 (104).  RC3H2 was identified using an imaging-based screen to look for 
increased levels of a fluorescently-tagged ASK1 following siRNA knockdown of a large 
candidate list of ubiquitin-related proteins.  After RC3H2 emerged as the best candidate 
from the screen, extensive western-based assays were performed to demonstrate that 
RC3H2 is capable of ubiquitinating ASK1 and thereby promoting its subsequent 
degradation (104).   
Another study found that the protein TNFAIP3 is also capable of interacting with 
ASK1 as an E3 and promoting its degradation (105).  One last pair of E3 ligases 
reported to ubiquitinate ASK1 are NEDD4 and NEDD4L.  ASK1 was found to be a 
substrate for each of these proteins and a binding partner of NEDD4L in a high-
throughput protein microarray study (106). 
In addition to the E3s discussed above, other protein-protein interactions with 
ASK1 have been described that promote ASK1 degradation by means other than 
directly coupling ubiquitin to ASK1.  Suppressor of cytokine signaling 1 (SOCS1) is one 
such protein that binds to ASK1 only when ASK1 is phosphorylated at Tyr-718 and 
promotes the degradation of ASK1 (83).  SOCS3 was also identified as an ASK1 
binding protein in the same study, with an observation that overexpression of SOCS3 
resulted in decreased ASK1 expression (83).  This suggested that SOCS3 behaves 
similarly to SOCS1, but no follow-up studies were performed (83).  In another study, 
SOCS1-mediated degradation of ASK1 was shown to be important for IL-6-induced 
protection against oxidant-induced lung injury in mice (107).  Beta-arrestins 1 and 2 
(ARRB1 and ARRB2) have both been reported to interact with ASK1 and promote its 
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degradation by acting as scaffold proteins to bring ASK1 into contact with CHIP (108).  
These studies highlight the importance of ubiquitin-mediation degradation of ASK1 as a 
regulatory mechanism to control MAPK signaling. 
While degradation of ASK1 can act as an important regulator of ASK1 signaling, 
there needs to be a way to control the targeting of ASK1 to the proteasome, otherwise 
efficient signal propagation could not occur.  An important means of blocking ubiquitin-
mediated proteolysis is through a deubiquitinase called ubiquitin-specific peptidase 9, X-
linked (USP9X).  This protein can bind to ubiquitinated ASK1 and remove the ubiquitin 
molecule, thus stabilizing ASK1 and preventing degradation (29).  Interestingly, Nagai 
et. al. showed that USP9X only binds ASK1 with kinase activity (it will not bind a kinase 
null mutant of ASK1) in response to oxidant stress.  This study also identified a 
ubiquitin-like sequence present in the c-terminus of ASK1 (Fig. I-2) that is required for 
binding (29).  Together, this suggests that there is some sort of conformational or 
protein-protein interaction change that occurs during activation of ASK1 and that 
exposes the c-terminal USP9X recognition sequence, thereby allowing USP9X to 
interact with ASK1. 
Another protein that seems to decrease degradation of ASK1 is GNA13.  The 
activated form of this protein is able to decrease the interaction between ASK1 and 
CHIP and thereby promote stabilization of ASK1 (109).  GNA13 and GNA12 have also 
been shown to promote an increase in ASK1 activity, which gives GNA13 the ability to 
stimulate ASK1 signaling and also assist in maintaining that signaling by blocking CHIP-
mediated degradation (109, 110).  Interestingly, Um et. al. reported that ASK1 could 
interact with components of the 19S regulatory subunit of the 26S proteasome and that 
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this interaction had a negative impact on proteasome function.  This affect was 
attributable to phosphorylation of a component of the 19S regulatory subunit by ASK1 
(111) and partially relied on the ubiquitin-like sequence present in ASK1 (112).  This 
report adds another layer to the degradation regulatory mechanism of ASK1, whereby 
upon activation ASK1 becomes ubiquitinated and thus targeted for proteasomal 
destruction.  But at the same time, ASK1 decreases the activity of the proteasome while 
USP9X works to remove the ubiquitin.  Thus, the ultimate fate of ASK1 depends on the 
interplay of these mechanisms, which likely can be tuned by the cell depending on the 
source or severity of the stress signal. 
 
ASK1 scaffold proteins 
 Several of the previously studied ASK1-interacting proteins serve as scaffold 
proteins that help to bring ASK1 into contact with its downstream MAP2Ks and MAPKs 
and thus enhance signaling through this pathway.  One such set of proteins is ARRB1 
and ARRB2, which were discussed above for their role as scaffold proteins to promote 
the degradation of ASK1.  In addition to this role, there have been other reports that 
suggest the beta-arrestins can also act as scaffolds for MAPK signaling downstream of 
ASK1.  Specifically, ARRB1 has been reported to serve as a scaffold for ASK1, MKK4, 
and JNK3 (113).  In this way, ARRB1 brings all three levels of the MAPK cascade 
together to enhance signaling in response to stress.  Another report added support to 
this scaffolding function of the beta-arrestins by using a peptide array to identify docking 
sites in ARRB1 and ARRB2 for JNK3, MKK4, and ASK1 (114). It is possible that the 
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arrestins may perform different regulatory functions for ASK1 depending on the cellular 
and stress context. 
 Another well-studied scaffold protein is ASK1-interacting protein 1 (DAB2IP), 
which was shown to enhance TNF-induced ASK1 signaling by recruiting components 
of the TNF receptor complex (including TRAF2) to ASK1 (115, 116).  Additionally, 
DAB2IP was shown to recruit PP2A to ASK1 to dephosphorylate Ser966 and promote 
14-3-3 dissociation from ASK1 (89, 117).  Similarly, the protein RB1CC1 seems to act 
as an important bridging protein that enhances the ASK1 and TRAF2 interaction and its 
depletion reduces this binding event (118).   
While DAB2IP and RB1CC1 bring some of the upstream TNF protein 
machinery into contact with ASK1 to potentiate signaling, other scaffold proteins help 
link ASK1 with its downstream target kinases.  Dual-specificity phosphatase 19 
(DUSP19) is one such protein which interacts with ASK1 and MAP2K7 and enhances 
ASK1 signaling through the JNK pathway (119).  Another protein called GEMIN5 was 
shown to behave similarly to the beta arrestins by acting as a scaffold to bring ASK1, 
MKK4, and JNK together to enhance ASK1-mediated signaling (120).  In a similar 
fashion, the scaffold protein MAPK8IP3 is known to be phosphorylated by ASK1, and 
this phosphorylation enhances the ability of MAPK8IP3 to link ASK1 to MAP2K4, 
MAP2K7, and JNK (121). 
A final family of scaffolding proteins that interact with ASK1 and regulate its 
function are the 14-3-3 proteins (122).  These proteins are present in many different 
multiprotein complexes and are known to bind to phosphoserine and phosphothreonine 
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motifs in their partner proteins (122).  The 14-3-3 proteins were shown to suppress 
ASK1 signaling by binding to ASK1 at the phospho-Ser-966 residue (123).  
Reciprocally, another study found that ASK1 activation was dependent on 
dephosphorylation of Ser-966 and subsequent dissociation of 14-3-3 proteins from 
ASK1 (88).  This negative regulatory role of 14-3-3 proteins on ASK1 was further 
confirmed in a mouse model of diabetic cardiomyopathy where a dominant negative 
mutant of a 14-3-3 isoform resulted in an increase in apoptosis (124).  Interestingly, the 
14-3-3 proteins have been found to act as docking sites for both ASK1 and ASK2 and 
may play a role in linking the functions of these two kinases (96).  In the same study, 
both knockdown of ASK2 and mutation of the 14-3-3 binding site on ASK2 also resulted 
in a decrease in 14-3-3 binding to ASK1 and increased ASK1 signaling (96). 
 
ASK1 positive regulatory interactions 
Several of the protein-protein interactions described above result in an 
amplification of signaling through the ASK1 pathway by bringing ASK1 into close 
contact with its downstream target kinases.  However, the scaffold proteins are not the 
only protein-protein interactions that positively regulate the function of ASK1.  One of 
the first positive regulators of ASK1 to be described was the death-domain associated 
protein DAXX (125).  DAXX was shown to promote FAS-mediated apoptosis through 
the ASK1 pathway by interacting with ASK1 (125, 126).  However, this enhancement of 
ASK1 signaling can be abrogated if DAXX binds to PARK7 or HSP27, which allows for 
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a highly nuanced control mechanism through just this one protein-protein interaction 
(127, 128). 
Dual-specificity tyrosine-phosphorylation-regulated protein kinase 1A (DYRK1A) 
has also been reported to increase the activity of ASK1 and possibly even 
phosphorylate ASK1 (129).  Likewise, eukaryotic translation initiation factor 2-alpha 
kinase 2 (EIF2AK2) also interacts with ASK1 and promotes ASK1 signaling (130).  
Interestingly, EIF2AK2 also may phosphorylate ASK1 or another protein interacting with 
ASK1 because a kinase-null mutant of EIF2AK2 abrogated ASK1 signaling (130).  
Another important positive regulator of ASK1 is the TNF receptor-associated factor 
(TRAF) family of proteins.  Specifically, TRAF proteins 1, 2, 3, 5, and 6 were initially 
reported to interact with ASK1 and promote signaling through the MAPK pathway (54).  
Later studies focused largely on the roles of TRAFs 2 and 6 in ASK1-mediated signaling 
in response to H2O2 and TNF in particular.  In all of these studies, the TRAF proteins 
were shown to be important interacting proteins that bound to ASK1 as TRX dissociated 
(31, 107, 118, 131, 132). 
 
ASK1 negative regulatory interactions 
While ASK1 does have several important protein-protein interactions that 
enhance signaling through its MAPK pathway, there are even more proteins that 
negatively regulate ASK1 in order to tightly control apoptosis.  For instance, apoptosis-
linked gene-2 (PDCD6) has been reported to bind to ASK1 and sequester it in the 
nucleus, thereby abrogating downstream JNK activation (133).  Another protein, 
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microspherule protein 1 (MCRS1), also exhibits a localization change upon binding to 
ASK1 (134).  In this case MCRS1 is largely nuclear, but when it is overexpressed with 
ASK1 a portion of MCRS1 becomes cytosolic and colocalizes with ASK1 (134).  
MCRS1 has been shown to negatively regulate ASK1 signaling and to dissociate from 
ASK1 upon ROS stress (134).  PARK7 has also been shown to bind to and negatively 
regulate ASK1 signaling in a redox-sensitive manner that depends on two key cysteine 
residues in PARK7 (135, 136).  RAF1 has also been shown to interact with ASK1 and 
negatively regulate ASK1 in a RAF1 kinase-independent manner (137). 
Some of the negative mechanisms of ASK1 have only been reported in specific 
contexts, like cyclin-dependent kinase inhibitor 1A (CDKN1A), which binds to ASK1 and 
blocks its signaling in response to rapamycin-induced stress (138).  Glutaredoxin 
(GLRX) was reported to interact with and inhibit ASK1 signaling in a redox-dependent 
manner (139).  GLRX association with ASK1 depended on the active site cysteines in 
GLRX, and overexpressed GLRX blocked ASK1 signaling in response to glucose 
deprivation (139).  Conversely, in a cellular environment with high glutamine levels, 
ASK1 was found to interact with glutaminyl-tRNA synthetase (QARS), which inhibited 
ASK1 signaling and dissociated from ASK1 in response to FAS signaling (140).  In the 
context of heat shock stress, GSTM1 was found to interact with and negatively regulate 
ASK1 (141).  Interestingly, in the context of this stressor and cell model system, GSTM1 
took the place of TRX for regulating ASK1 (141). 
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ASK1 kinase target proteins and pathway crosstalk 
 The majority of the ASK1-interacting proteins that have been identified act as 
regulators of ASK1 in a variety of cellular contexts, but some of them are actually 
regulated by ASK1.  The main target proteins of ASK1 are the four downstream MAP2K 
kinases in the P38 and JNK pathways.  MAP2K4/7 and MAP2K3/6 were elucidated as 
downstream targets of ASK1 in the same publication that first described ASK1 (27).  
Since then, many other studies have provided additional evidence for the role of ASK1 
in phosphorylating and activating these MAP2Ks (91, 113, 119-121, 126, 136, 138, 142-
144).  In addition to the MAP2K proteins, ASK1 also phosphorylates some of its adapter 
proteins like MAPK8IP3 (see previous section for discussion) to enhance ability of the 
scaffold proteins to bind to ASK1 and downstream targets of ASK1 (121). 
 ASK1 was recently found to influence the GAPDH-SIAH1 stress response 
pathway by phosphorylating SIAH1 in response to oxidative stress (145).  Thus, ASK1 
not only activates its own intrinsic pathway in response to stress, it also can modulate 
other stress response pathways, which underscores the importance of this stress 
transducer.  Another example of pathway crosstalk involves the death-associated 
protein DAXX.  As discussed above, DAXX is a positive regulator of ASK1 and 
enhances ASK1 signaling in response to FAS.  In addition to that, DAXX is also a 
downstream target of ASK1 (146).  ASK1 phosphorylates DAXX to control its 
subcellular localization (nuclear vs cytosolic) and to promote polyubiquitination of DAXX 
(146, 147).  This polyubiquitination induces a positive feedback mechanism, whereby 
ASK1 activation is enhanced by binding to the ubiquitinated DAXX (147).  As a final 
example of pathway crosstalk, ASK1 was shown to interact with MAP3K7 and to 
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decrease the ability of MAP3K7 to signal through the NF-B pathway in response to IL-
1 (148).  More recently, another study showed that this pathway crosstalk be 
bidirectional when they demonstrated that MAP3K7 and one of its partner proteins 
(TAB2) could inhibit ASK1 signaling (149). 
 
Outstanding questions in ASK activation and signal transduction 
 As can be seen from all of the protein-protein interactions discussed in the 
sections above, ASK1 interacts with a wide variety of proteins that each can exert a 
different regulatory effect on the function of ASK1.  From the ubiquitin system controlling 
ASK1 stability to the scaffold proteins that control ASK1 protein-protein interactions, as 
well as the myriad interactions that negatively or positively regulate ASK1 and the 
crosstalk between several stress-signaling cascades, the picture of ASK1 regulation is 
quite complex.  Additional complexity comes from the fact that ASK1 can be activated 
by several chemically diverse species and that several of the protein-protein interactions 
may be specific for one type of stressor.   
 There are two major questions about the function of ASK1 that remain 
unanswered.  Because the many different chemical species to which ASK1 responds 
are capable of interacting with and modifying proteins in different fashions, it remains 
unknown how ASK1 senses all of these stress signals and transduces them into a 
single response.  There has been some investigation into this area, but no comparative 
study between an oxidant and an electrophile has been carried out. 
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The second major question is whether or not the hypothesized ASK1 
signalosome exists and, if it does, what the exact membership of this multiprotein 
complex might be.  The evidence for the presence of an ASK1 signalosome comes from 
the synthesis of the size exclusion experiment by Noguchi et. al. (93) and the large 
number of identified binary interacting proteins of ASK1 discussed above.  Thus, a large 
multiprotein complex composed of some or all of these interacting proteins is certainly a 
plausible explanation for the data.  However, this hypothesis has not been rigorously 
tested and a more thorough investigation of the protein-protein interactions that regulate 
ASK1 needs to be undertaken.   
Until now, the vast majority of work in the ASK1 field has used relatively low 
throughput techniques, including Western blot, yeast-two-hybrid, and in vitro kinase 
assays, to examine how one or a few proteins influence ASK1.  What is missing from 
the literature is a picture of how all of these interactions behave at one time in response 
to a stimulus.  Additionally, most of this work has been performed with techniques that 
rely on antibodies with poorly characterized specificity and with assays that are largely 
qualitative or semi-quantitative at best.  Using the techniques mentioned above, a 
complex-wide investigation of the ASK1 signalosome would be nearly impossible; 
however, by leveraging the speed, specificity, and superior quantitative capabilities of 
mass spectrometry (MS) techniques, such an examination becomes tenable.  
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Analytical techniques to study protein interactions and modifications 
 
MS-based proteomics overview 
 Since the introduction of the electrospray ionization technique by Fenn and 
Yamashita the field of MS-based proteomics has grown exponentially (150, 151).  With 
the coupling of this ionization technique to tandem MS (MS/MS) instrumentation, the 
analysis of proteins at a true “omics” level has become routine (152, 153).  While early 
MS-based proteomics studies could identify dozens of proteins in one hour, modern 
mass spectrometers can identify over five thousand proteins in the same amount of time 
(154-157).  There are many different types of MS assays that are employed to 
investigate the proteome, but the most common type is the bottom-up or “shotgun” 
method. 
Liquid-chromatography tandem MS (LC-MS/MS or shotgun MS) assays are 
analyses of a peptide mixture by MS from which the proteins initially present in the 
mixture are inferred.  To start, a protein mixture is digested with a protease (typically 
trypsin) to generate peptides.  These peptides are then separated by reverse phase 
liquid chromatography in line with the MS instrument.  Once eluted from the 
chromatography column into the MS instrument,  a peptide  is selected and then 
fragmented  along the peptide bond backbone.  These fragments are analyzed and 
recorded in an MS2 spectrum which contains all of the sequence information for that 
peptide (Fig, I-7).  This procedure is repeated thousands of times in a single 
experiment, and this collection of MS2 data is analyzed via sophisticated computer 
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algorithms (152, 158-162).  These algorithms predict what the fragmentation pattern for 
every possible peptide in the proteome is and then match these theoretical spectra to 
the experimental MS2 spectra to assign an identity to the peptide along with a score for 
how well the experimental spectrum matches the theoretical one. 
Once each MS2 spectrum in a datafile has been assigned to a peptide, a 
minimum threshold score is applied to the dataset and all peptides that pass this 
threshold are used to infer the identity of the proteins that were originally present in the 
sample prior to proteolytic digestion.  In addition to the identification of the proteins in 
the sample, this technique has inherent quantitative data about the abundance of the 
proteins present in the form of the number of MS2 spectra identified for each protein 
(termed spectral counting), which can be used to examine expression-level differences 
in a protein across different conditions (163, 164).  There are many other MS-based 
techniques employed in the field of proteomics, but the basic shotgun analysis with 
spectral counting outlined above is the foundation for several of the more sophisticated 
applications discussed below. 
 
MS-based analysis of phosphorylation and other post-translational modifications  
 The majority of the ASK1 phosphorylation sites described above were discovered 
using mutational analysis to identify the site and the functional importance of having a 
phosphorylation present on a particular residue.  While this is a highly accurate way of 
describing a phosphosite, it is a slow and laborious process as it is difficult to know what 
residue to mutate a priori.  Thus at best, one is able to narrow down to a region by use 
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of deletion mutants and then begin mutating potential residues one at a time.  As 
discussed above, ASK1 has over 200 serine, threonine, and tyrosine residues so 
attempting to mutate each one in series to determine if that site is biologically important 
is not practical.  The current state-of-the-art approach to this problem is to utilize MS 
proteomic assays to identify phosphorylated peptides (and other post-translational 
modifications [PTMs]), thus removing the guesswork and pin-pointing the exact residue 
that needs to be mutated for additional analyses (165-172).  In fact, MS analyses can 
even be utilized to determine the biological importance of a particular phosphorylation to 
a certain extent by tracking the amount of the phosphorylated peptide present under 
different conditions (173).  This is analogous to performing a Western blot with an 
antibody directed against the phosphorylated form of the protein, but the MS analysis 
has the advantage of a faster development time and better specificity than an antibody-
based approach. 
 Phosphorylations and other PTMs are typically present at a low amount in the 
cellular environment with the modified version of the protein only making up a few 
percent of the total amount of that protein present.  Because of this, an enrichment step 
is often used to aid in identification of the phosphorylated peptide.  Depending on the 
scale of the analysis, this enrichment step could be an epitope tag on a single protein or 
an antibody against phosphotyrosine residues, or an immobilized metal affinity column 
to enrich all phosphorylated peptides.  In the latter two cases, digestion of the protein is 
carried out prior to the enrichment step, while in the case of a single protein analysis the 
enrichment step is carrier out first (166, 174, 175).  Following digestion, the most 
common approach for this kind of experiment is a shotgun MS analysis (Fig. I-7). 
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Figure I-7.  Shotgun phosphoproteomics.  Pathway 1 illustrates the concept of purifying a 
single protein and analyzing it for PTMs (yellow stars) while pathway 2 illustrates a global 
approach.  Following enrichment, the peptides are analyzed via shotgun MS methods. 
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 With the current generation of MS instruments, experiments identifying hundreds 
or thousands of individual phosphorylated peptides in a single run have become routine 
(167, 169, 176).  The confident identification of phosphopeptides by MS was greatly 
aided by the introduction of the Thermo Scientific Q Exactive mass spectrometer and 
the subsequent iterations of it (177-180).  The Q Exactive combines two distinct 
advantages over previous generations of instruments – higher energy collision induced 
dissociation (HCD) fragmentation and utilizing the Orbitrap as the mass analyzer for 
both MS1 and MS2 scans.  Most previous instrumentation only used a high resolution 
scan for the MS1 spectrum, which meant that a researcher had high confidence in the 
mass-to-charge ratio of the peptide precursor with typical mass errors at 10 parts-per-
million (ppm) or less, but the MS2 scan was done with a low resolution mass analyzer 
which could have mass errors of half a dalton or more.   
By using a Q Exactive, a researcher could have both MS1 and MS2 scans with 
less than 10 ppm mass error which greatly increases confidence in identification and 
especially helps with localizing a phosphorylation to a particular amino acid in a peptide 
if more than one potential phosphorylation site was present.  Phosphorylated peptides 
are characterized by a mass shift of 79.966 daltons which is observable at both the MS1 
and MS2 level – the Q Exactive allows one to very precisely observe this shift and rule 
out potential false positives.  Additionally, by utilizing HCD fragmentation, all fragment 
ion information is retained as opposed to earlier instrumentation which utilized CID 
fragmentation in an ion trap that resulted in the loss of any fragment mass less than 1/3 
of the precursor mass (181).  All of this adds up to better quality spectra that will be 
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analyzed by the search algorithms mentioned above, which results in improved 
identifications. 
 While these matching algorithms are very robust, they are not perfect and do 
falsely identify some spectra as being a phosphorylated peptide when it is not.  In order 
to combat this, the best practice is to manually validate any automated assignment of a 
PTM identification.  There are well established protocols to ensure that the assignment 
from the automated algorithm is correct and are covered in detail elsewhere (182-184).  
In brief, the purity of the collected precursor is confirmed, mass accuracy of MS1 and 
MS2 fragments are checked and should be within tolerable limits (10 ppm on a Q 
Exactive), and fragment peaks are assigned to b and y ions and any neutral loss peaks. 
 The procedure described above can be applied to any post-translational 
modification of a known mass.  For example, HNE Michael adducts could be identified 
by searching for peptides with a mass shift of 156.115 daltons (158.130 if reduced) on a 
cysteine, histidine, or lysine residue (185).  Here again, the use of a Q Exactive 
instrument improves the identifications of adducted peptides for the same reasons 
detailed above – higher accuracy on MS1 and MS2 data coupled with HCD 
fragmentation provides much more confident identifications.  As an example, our lab 
performed two proteome-wide studies aimed at identifying proteins adducted by HNE 
through the use of an alkynyl analogue of HNE that was post-coupled to biotin via a 
copper catalyzed cycloaddition reaction.  In the first study, a lower resolution LTQ 
instrument was used and over 1000 adduct proteins were identified (24).  However, no 
specific adduct sites were mapped due to limitations in the instrumentation and 
methodology.  Thus confirmation of the adducted proteins relied on examining the 
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concentration-response relationship of the identified proteins.  In contrast to this, a later 
study by our lab used a similar technique, but analyzed on a Q Exactive and identified 
almost 400 HNE adduct sites on over 300 proteins (25).  In this study, the identification 
of the HNE adduct proteins was much more certain than the earlier study because of 
the site-specific MS2 annotations, which provided direct evidence of peptide and protein 
adduction. 
 
Affinity Purification Mass Spectrometry (AP-MS) methodology 
 Classically, protein-protein interaction studies have been done via techniques 
such as yeast two-hybrid or co-IP westerns, and these types of studies comprise the 
majority of the ASK1 literature (186, 187).  Increasingly, though, mass spectrometry is 
becoming the method of choice for studying protein interactions (187-192).  Typically 
referred to as affinity purification mass spectrometry (AP-MS), this technique combines 
an affinity enrichment step to purify the protein of interest (the bait protein) followed by 
mass spectrometry to identify the interacting proteins (the prey proteins) (193).  The bait 
protein is most often ectopically expressed in a cell model system and is also tagged 
with an epitope (FLAG, HA, etc.) to allow for immunoaffinity enrichment of it and its prey 
proteins (Fig. I-8) (193, 194).  Many studies have employed variations on this technique, 
with the majority of the diversity being in the way in which the samples are obtained and 
the proteins purified.  The final mass spectrometry step is almost always a standard 
shotgun analysis to identify the bait and prey proteins.  This type of method has been 
successfully used to investigate many different proteins and their interactors in several 
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biological contexts.  A recent study established a highly standardized way of preparing 
samples and validating the data and applied it to a set of over 5,000 bait proteins with 
more than 50,000 interactions identified so far (195).  Another study established the 
reliability of this type of study by demonstrating that inter-lab reproducibility for AP-MS 
studies is quite high (196). 
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Figure I-8. General Scheme for an AP-MS experiment.  A tagged bait protein is 
expressed in cells and then interacting prey proteins are co-purified with the bait 
protein using the tag.  Finally, the purified protein complexes are analyzed via mass 
spectrometry. 
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AP-MS Data analysis and informatics 
 One major drawback to an AP-MS experiment is that there are many false 
positive interactions represented in the inventories obtained in AP-MS analyses.  These 
false positives come from a variety of sources (Fig. I-9) (197).  Confidently excluding 
these while still maintaining high accuracy for the true positive prey proteins is 
challenging.  Initially, false positives could only be managed by carefully designing the 
affinity purification steps to minimize contaminant proteins and by using negative control 
experiments to generate a list of proteins to exclude from the final analysis (197).  While 
certainly necessary, these methods are not sufficient on their own to eliminate all of the 
false positives and often are too stringent – resulting in the removal of true protein-
protein interactions that are present in the control at a much lower level.   
Recently, there have been several algorithms published that were designed to 
assign confidence values to AP-MS results by taking advantage of the inherent 
quantitative data present in MS experiments (186, 198-203).  The most widely used of 
these algorithms is called Significance Analysis of INTeractome (SAINT) and was 
designed by the Nesvizhskii group (201).  SAINT works by comparing spectral count or 
MS1 intensity distributions from negative control purifications (samples lacking the 
tagged bait protein that are passed through the full sample workup procedure) to the 
distributions from the bait purifications and then calculates the probability that each prey 
is a true interactor with each bait (201, 202).  This then allows the user to filter their AP-
MS data by a confidence value, which eliminates most of the false positives.  A web-
based version of this technology was also created along with a pre-populated database 
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of hundreds of negative control experiments for a variety of conditions to allow anyone 
to perform a SAINT analysis, even if they did not have their own control data (204). 
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Figure I-9.  Sources of false positive identifications in AP-MS studies.  NS = Non-
specific interaction. 
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MS-based protein-protein interactions for ASK1 
 Only a few mass spectrometry-based studies have reported ASK1 protein-protein 
interactions and none of them were focused on ASK1.  In one study, ASK1 was found to 
interact with anaplastic lymphoma receptor tyrosine kinase (ALK) via a one-dimensional 
SDS page LC-MS/MS method (205).  Another paper reported a system-wide autophagy 
study and found ASK1 associated with PRKAA2 and PRKAB2 (206).  Finally, a more 
recent study performed an overexpression-based protein-protein interaction study for 
over 100 kinases and identified ATPase family, AAA domain containing 3A (ATAD3A) 
and nucleus accumbens associated 1, BEN and BTB (POZ) domain containing 
(NACC1) as ASK1 interactors (207). 
 
Targeted Protein Quantitation 
Parallel Reaction Monitoring (PRM) 
 As discussed above, a shotgun MS analysis is the most common MS technique 
applied in an AP-MS experiment, but it is not the only method that can be used.  
Another approach is to follow affinity enrichment with a targeted MS analysis using 
multiple reaction monitoring (MRM) or parallel reaction monitoring (PRM) (208-213).  
This is not as commonly performed because AP-MS experiments are typically done as 
discovery experiments when interactions for a protein are not known.   If, however, one 
does know what the interacting proteins for a particular bait protein of interest are, then 
a targeted assay can be performed to test hypotheses about how these interactions 
may change in response to various conditions.  This MS analysis provides better 
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quantitation and fewer missing data points, since a particular set of peptides 
(representing the proteins of interest) are targeted with known elution times and MS/MS 
spectra.   
In a PRM assay, a peptide mixture is eluted off a column into a Q Exactive, 
where the precursor ion of interest is isolated in the first quadrupole and collected in the 
C-trap (179, 209).  After a sufficient number of ions have been collected, they are 
fragmented in the HCD cell and then analyzed in the Orbitrap, where a complete 
MS/MS spectrum is collected (Fig. I-10) (209, 210, 214).  After the data are collected, 
the fragment ions are extracted from the chromatogram and a peptide peak area is 
calculated.  Comparison of this peptide peak area across conditions allows one to see 
whether the abundance of the targeted protein changes between samples (Fig. I-11).  
From this information, changes in protein-protein interaction with changing conditions 
can be inferred.  If peptide standards that include lysine or arginine residues uniformly 
labelled with heavy isotopes (stable isotope dilution – SID) are included in the 
experiment, then absolute quantitation of the peptides and stoichiometric calculations of 
the protein-protein interactions can be performed (208, 215-218). 
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Figure I-10.  PRM method in a Q Exactive.  (1) Targeted peptides are isolated by Q1. 
(2) Isolated peptides are fragmented in the HCD collision cell. (3) Fragment ions are 
transferred back into the C-trap. (4) Fragment ions are analyzed in tandem by the 
Orbitrap and an MS2 spectrum is recorded. Figure adapted from Gallien et al. Mol Cell 
Proteomics 2012;11:1709-1723. 
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Figure I-11.  Development and analysis of PRM assay.  (1) Target protein FASTA 
sequence is acquired and digested with trypsin in silico (2) Proteotypic peptides of target 
protein are selected for PRM analysis (3) Peptide fragment ions are selected post-
acquisition based on performance (4) The top three fragment ions are integrated across 
the dataset (5) Integrated peak areas are compared across runs 
 53 
Research Objectives and Approach 
Questions and objectives 
 As discussed above, there are two major questions in the ASK1 field regarding 
its activation in response to diverse stress stimuli.  The first deals with understanding 
how ASK1 is able to transduce several chemically distinct stressors into a single 
biological pathway response.  The second question deals with the existence of the 
hypothesized signalosome as a unifying construct for all of the protein-protein 
interactions discussed above.  The activation of ASK1 has primarily been studied using 
H2O2, but for the work presented in this dissertation, I chose to examine ASK1 activation 
in response to HNE, as it is a relevant, endogenously produced product of lipid 
oxidation that acts via a completely different mechanism than H2O2 and thus may 
present new mechanistic insight into the function and regulation of ASK1.  Therefore, 
the specific questions that this dissertation addresses are: (1) what is the composition of 
the hypothesized ASK1 signalosome and how does this composition change in 
response to HNE stress and (2) how does ASK1 respond to alkylation stress by HNE?   
 I hypothesized that ASK1 or its complex members are modified by electrophiles 
(represented by HNE), resulting in pathway activation and formation of a consensus 
post-activation signalosome, along with a change in the phosphorylation pattern on 
ASK1.  Chapter II discusses the application of mass spectrometry methodology to track 
the dynamic changes in the composition of the putative signalosome complex in 
response to HNE stress.  Chapter III discusses the use of mass spectrometry to identify 
HNE adduction sites on ASK1 and how that adduction correlates with activation of the 
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ASK1 pathway and changes in the phosphorylation state of ASK1.  The major aims of 
my dissertation research were: 
 
1. Determine the consensus composition of the pre- and post-activation ASK 
signalosome in an over-expression and endogenous-expression cell model 
system. 
2. Track the dynamics of the signalosome composition in response to an increasing 
concentration of HNE treatment. 
3. Identify the sites of covalent HNE adduction on ASK1. 
4. Map phosphorylation sites on ASK1 and correlate changes in site occupancy 
with HNE treatment and adduction. 
 
A secondary goal of this research was to demonstrate the utility of AP-PRM for 
determining the stoichiometry of a protein complex and examining compositional 
changes in multiprotein complexes in response to stimuli.  A discussion of using AP-
PRM for these purposes compared to more traditional means is presented in chapter IV. 
 
Approach 
 To test the hypothesis that ASK1 is modified by HNE, resulting in pathway 
activation and signalosome rearrangement, a suitable model system expressing ASK1 
was developed and AP-PRM assays were performed to track changes in signalosome 
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composition in response to treatment.  These studies are discussed in chapter II, in 
which three different components of the ASK1 signalosome were expressed in cells and 
the resulting AP-PRM data from these cell lines were combined to generate a 
comprehensive view of the changes in complex formation that occur as a result of HNE 
insult.  These results were compared to a similar experiment performed in the context of 
endogenous expression of the ASK1 protein to verify the results.  Additionally, in 
chapter III, immunopurified ASK1 treated with HNE was examined to identify and 
localize sites of HNE adduction at different HNE concentration levels.  These adduction 
sites were compared with changes in phosphorylation at the same HNE concentrations 
in order to correlate the consequences of adduction with functional changes in ASK1.  
The phosphorylation changes in response to HNE were also compared to the changes 
in phosphorylation that occur on ASK1 in response to H2O2 and the HNE adduct sites 
were compared to sites of cysteine oxidation as a function of H2O2 treatment.  This 
comparison allowed for a detailed look at how ASK1 differentially senses oxidative and 
electrophilic stress.  All of these results together generated a view of how ASK1 
responds to electrophile stress (modelled here with HNE) at both the PTM and protein-
protein interaction level, which had been completely lacking in our understanding of this 
important system until now. 
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Table I-1.  ASK1 Protein-Protein Interaction Table 
Protein 
Regulation 
(POS/NEG) 
Mechanism 
Experimental 
Method(s) 
Reference(s) 
AKT1 NEG 
Phosphorylates ASK1 at 
Ser-83 
Co-IP Western, 
OE, Endog. 
(85) 
ALK - - AP-MS (205) 
ARRB1 &  
ARRB2 
POS/NEG 
Act as a scaffold to bring 
ASK1 into contact with 
CHIP for degradation and 
into contact with MAP2K4 
and JNK for signaling in 
different contexts 
Co-IP Western, 
OE, RNAi, 
Peptide array, 
Kinase assay 
(108, 113, 114) 
ASK1 POS 
Dimerizes and 
autophosphorylates itself 
Co-IP Western (31) 
ASK2 - 
Forms heteromeric 
complex with ASK1.  
Conflicting reports on 
regulatory role. 
Co-IP Western, 
OE, AP-MS, Y2H 
(36, 71, 94-96, 
207) 
ASK3 - - AP-MS This study 
ATAD3A - - AP-MS (207) 
BIRC2 NEG Ubiquitinates ASK1 
Western, 
functional KD 
(103) 
CDC25A NEG 
Dephosphorylates ASK1 
Thr-838 
Co-IP Western, 
OE, Endog., 
Functional.   
(92) 
CDKN1A NEG 
Binds to ASK1 and blocks 
rapamycin-induced stress 
Co-IP Western, 
OE 
(138) 
CREBBP - - Y2H (219) 
DAB2IP POS 
Scaffold protein that links 
ASK1 to TNF receptor 
complex to enhance 
signaling 
Co-IP Western, 
OE, functional KD 
(89, 115-117) 
DAXX POS 
Promotes ASK1 signaling, 
target of ASK1 
Co-IP Western, 
OE, IVK, ICC 
(125-128, 146, 
147) 
DMD - - Y2H (219) 
DUSP19 POS 
Scaffold protein that links 
ASK1 to MAP2K7 
Co-IP Western, 
OE, IVK 
(119) 
DYRK1A POS 
Promotes ASK1 signaling, 
may phosphorylate ASK1 
Co-IP Western, 
OE, IVK 
(129) 
EIF2AK2 POS Promotes ASK1 signaling 
Co-IP Western, 
OE, IVK, ICC 
(130) 
EP300 - - Y2H (219) 
GADD45B - Interacts with ASK1 
Co-IP Western, 
OE 
(220) 
GAPDH - 
Enhances ASK1 binding to 
SIAH1 
Co-IP Western, 
OE, Endog. 
(145) 
GEMIN5 POS 
Scaffold protein that links 
ASK1 to MAP2K4 and JNK 
Co-IP Western, 
OE, IVK 
(120) 
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Protein 
Regulation 
(POS/NEG) 
Mechanism 
Experimental 
Method(s) 
Reference(s) 
GLRX NEG Inhibits ASK1 signaling 
CO-IP Western, 
OE, IVK 
(139) 
GNA12 POS Promotes ASK1 activity 
Co-IP Western, 
OE 
(109, 110) 
GNA13 POS 
Blocks ASK1-CHIP 
interaction, promotes 
ASK1 activity 
Co-IP Western, 
OE 
(109, 110) 
GSTM1 NEG 
Inhibits ASK1, dissociates 
after heat shock 
Co-IP Western, 
OE, IVK 
(141) 
HSPA1A/ 
HSPA4 
NEG 
Disrupts ASK1 n-terminal 
homophilic interaction and 
works with CHIP as a co-
E3 
Co-IP Western, 
OE, Endog, 
kinase assay 
(100, 102) 
HSP90AA1 - - 
Identified in a 
HTS as an 
interactor 
(221) 
JAK2 NEG 
Phosphorylates ASK1 
Y718 
Co-IP Western,  
OE, kinase assay 
(84) 
MAP2K3/6 - Target of ASK1 
Co-IP Western, 
OE, Endog., IVK 
(27, 91, 136, 
138, 142, 143) 
MAP2K4/7 - Target of ASK1 
Co-IP Western, 
OE, Endog., IVK 
(27, 113, 119-
121, 126, 144) 
MAP3K7 NEG 
Target of ASK1, inhibits 
ASK1 signaling 
Co-IP Western, 
OE 
(148, 149) 
MAPK8IP3 POS 
Scaffold protein that links 
ASK1 to MAP2K4/7 and 
JNK 
Co-IP Western, 
OE, Endog. 
(121) 
MCRS1 NEG Inhibits ASK1 activity 
Co-IP Western, 
OE, Endog., ICC 
(134) 
NACC1 - - AP-MS (207) 
NEDD4 - Ubiquitinates ASK1 
HTS, protein 
microarray 
(106) 
NEDD4L - Ubiquitinates ASK1 
HTS, protein 
microarray 
(106) 
PARK7 NEG Inhibits ASK1 activity 
Co-IP Western, 
OE, IVK 
(135, 136) 
PDCD6 NEG 
Binds to ASK1 and 
translocates it to the 
nucleus 
Co-IP Western, 
OE, ICC 
(133) 
PIM1 NEG 
Phosphorylates ASK1 Ser-
83 
Co-IP Western. 
OE. Endog. 
(86) 
PPP5C NEG 
Dephosphorylates ASK1 
Thr-838 
Co-IP Western 
Y2H, OE, ICC, 
Endog 
(91) 
PRDX1 POS 
May form a mixed-disulfide 
with ASK1 to transduce 
H2O2 signaling 
Co-IP Western, 
OE 
(222) 
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Protein 
Regulation 
(POS/NEG) 
Mechanism 
Experimental 
Method(s) 
Reference(s) 
PRKAA2 - - AP-MS (206) 
PRKAB2 - - AP-MS (206) 
Proteasome NEG 
Degrades ASK1, but ASK1 
can phosphorylate it and 
decrease activity 
Co-IP Western, 
OE, functional. 
(111) 
PTPN11 POS 
Dephosphorylates ASK1 
Y718 
Co-IP Western, 
OE 
(84) 
QARS NEG 
Binds to ASK1 in context 
of high glutamine 
environment and inhibits 
signaling 
Co-IP Western, 
OE, IVK 
(140) 
RAF1 NEG Inhibits ASK1 
Co-IP Western, 
OE 
(137) 
RB1CC1 POS 
Scaffold protein that links 
ASK1 to TRAF2 
Co-IP Western, 
OE 
(118) 
RC3H2 NEG Ubiquitinates ASK1 
OE, Endog, Co-IP 
Western, HTS 
(104) 
SIAH1 - Target of ASK1 
Co-IP Western, 
OE, Endog. 
(145) 
SMN1 - 
ASK1 blocks ubiquitination 
of SMN1 
Co-IP Western, 
OE 
(223) 
SOCS1 NEG 
Promotes ASK1 
degradation 
OE, Co-IP 
western 
(83, 107) 
SOCS3 NEG? 
Promotes ASK1 
degradation  
OE, Co-IP 
western 
(83) 
STUB1 NEG Ubiquitinates ASK1  
Western, OE, in 
vitro system, 
functional KD 
(100, 101) 
TNFAIP3 NEG 
Promotes ASK1 
degradation 
OE, Co-IP 
western 
(105) 
TRAFs POS Promotes ASK1 activity 
Co-IP Western, 
OE, Endog 
(31, 54, 107, 
118, 131, 132) 
TRX NEG 
Binds to ASK1 N-terminus 
and inhibits activity.  
Promotes ubiquitination. 
Y2H, Co-IP 
Western, OE 
(31, 38, 97) 
USP9X POS 
Deubiquitinates ASK1 and 
promotes protein stability 
Co-IP Western, 
OE, Endog., 
Mutagenesis 
(29) 
14-3-3 NEG 
Binds to ASK1 at pSer966 
and blocks signaling.  Acts 
as a bridge between ASK1 
and ASK2 
Co-IP Western, 
OE, Endog. 
(88, 96, 117, 
122-124, 224) 
Table 1.  Reported ASK signalosome member proteins and their regulation of ASK1.  
OE=Over Expression, Endog.= Endogenous expression, Co-IP – 
coimmunoprecipitation, Y2H = yeast two-hybrid, HTS=High Throughput Screen, AP-MS 
= Affinity Purification Mass Spectrometry, IVK = in vitro kinase assay, ICC = 
immunocytochemistry 
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CHAPTER II 
 
ASSEMBLY DYNAMICS AND STOICHIOMETRY OF THE APOPTOSIS SIGNAL-
REGULATING KINASE (ASK) SIGNALOSOME IN RESPONSE TO ELECTROPHILE 
STRESS 
 
 
Introduction 
 
As discussed in chapter 1, ASK1 is hypothesized to be regulated by a large 
multiprotein complex termed the ASK signalosome (1) where proteins dynamically 
assemble around ASK1 as either an inactive or active signaling complex [recently 
reviewed in (2)].  The exact composition of this complex has not yet been determined, 
but over 90 proteins have been identified as ASK1-interacting proteins (see Table I-1). 
These interacting proteins have most commonly been identified using co-
immunoprecipitation (co-IP) and Western blot methods in ASK1-overexpressing cells.  
Thus, although the ASK1 system is currently best understood as a series of binary 
interactions, there is evidence that ASK1 exists in a high molecular mass “pre-
activation” complex of ~1500 kDa that undergoes protein compositional or 
stoichiometric remodeling to form an even higher mass “post-activation” complex upon 
treatment with H2O2 (3).   
The majority of the reported ASK1 protein-protein interactions have been 
investigated in the context of H2O2-mediated activation of the system but many other 
chemicals are known to activate ASK1 (1, 4-20).  I chose to investigate the ASK1 
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system in the context of exposure to the lipid electrophile 4-hydroxy-2-nonenal (HNE), 
which is a physiologically relevant stressor generated endogenously under conditions of 
oxidative stress (21, 22) that I and others (5) have shown to be capable of activating the 
ASK1 pathway.  Unlike the reversible oxidation caused by H2O2, electrophile stress is 
characterized by covalent (non-reversible) adduction of cellular nucleophiles, 
particularly protein Cys residues (21-24).  Due to this mechanistic difference between 
H2O2-induced oxidative stress and HNE-induced electrophile stress, I reasoned that the 
mechanisms of ASK1 regulation may vary between these two stressors. Thus, studies 
of HNE-induced electrophile stress may reveal new insights into how the ASK system is 
able to respond to diverse stress signals.  
To better define the molecular composition of the ASK system and its regulation 
in response to HNE, I used quantitative mass spectrometry to gain an “all components” 
view of ASK1-interacting proteins.  I hypothesized that a subset of the previously 
reported ASK1-interacting proteins would constitute the ASK signalosome in unstressed 
cells and that the composition and stoichiometry of the complex would change in 
response to HNE stress.  Here I report a systematic investigation of ASK signalosome 
components and the response of this signalosome to HNE treatment. I employed an 
affinity purification-mass spectrometry (AP-MS) approach with data-dependent shotgun 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) and parallel reaction 
monitoring (PRM) methods to study four related cell models with both over-expression 
and endogenous expression of ASK1, ASK2, and ASK3 proteins. 
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Experimental Procedures 
 
DNA constructs 
Tandem-tagged constructs for ASK1, ASK2, and ASK3 were generated in 
pcDNA3.1 plasmids (V790-20, Life Technologies, Grand Island, NY) from Genscript 
(Piscataway, NJ).  The ASK1 sequence previously described (25) was modified by 
substituting the HA tag with a tandem HA-FLAG tag.  Partial clones of ASK2 containing 
the catalytic portion of each protein (plasmid # 23853) and ASK3 (plasmid # 23499) 
were obtained from Addgene (Cambridge, MA) and were originally created by William 
Hahn & David Root (26).  The missing gene fragments were synthesized by Genscript 
and a tandem tag sequence was added to each gene (HA-V5 for ASK2 and HA-Myc for 
ASK3).  All three plasmids are available from Addgene (ASK1 - #69726, ASK2 - 
#69727, ASK3 - #69728). 
 
Antibodies 
Co-IPs of epitope-tagged proteins were performed with either EZview red anti-HA 
beads (Sigma-Aldrich, St. Louis, MO, E6779), EZview red anti-FLAG beads (Sigma-
Aldrich, F2426), EZview red anti-Myc beads (Sigma-Aldrich, E6654), or Anti-V5 agarose 
affinity gel (Sigma-Aldrich, A7345).  The endogenous ASK1 IPs were performed using 
sc-5294 AC (Santa Cruz Biotechnology, Dallas, TX). 
ICC staining was performed with the following primary antibodies at 1:500 
dilutions: Beta Tubulin (ab7792), V5 (ab9116), and Myc (ab9132) purchased from 
Abcam (Cambridge, MA); ASK1 (sc-5294) purchased from Santa Cruz Biotechnology; 
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HA (71-5500) purchased from Life Technologies (Carlsbad, CA); and FLAG (8146S) 
purchased from Cell Signaling Technology (Danvers, MA).  Secondary staining for ICC 
was done with the following antibodies from Life Technologies at 1:500 dilutions: anti-
rabbit 633 (A21071), anti-goat 546 (A11056), and anti-mouse 488 (A21202). 
Western blots were performed with the following primary antibodies: FLAG 
(8146S), ASK1 phospo-T845 (3765S), JNK (9252S), phospho-JNK (4668S), p38 
(9212S), and phospho-p38 (9211S) purchased from Cell Signaling Technology; ASK1 
(sc-5294) purchased from Santa Cruz Biotechnology; ASK2 (ab99426) and ASK3 
(ab76806) purchased from Abcam; and ATAD3A (H00055210-D01P) and ATAD3B 
(H00083858-B01P) purchased from Novus Biologicals (Littleton, CO).  Secondary 
antibodies were from Life Technologies: anti-mouse 680 (A21058), anti-rabbit 680 
(A21109), and anti-goat 680 (A21084).   
 
Cell lines and cell culture 
HEK-293 cells (CRL-1573, ATCC) were grown in DMEM (Life Technology, 
12430) supplemented with 10% fetal bovine serum (Atlas Biologicals, Fort Collins, CO) 
at 37°C in a humidified atmosphere with 5% CO2.  ASK1, 2, and 3 expressing cell lines 
were generated from HEK-293 cells by transfecting the corresponding expression 
plasmids into cells using Lipofectamine 2000 (Life Technologies, 11668019) following 
the manufacturer’s instructions.  Twenty-four hours following transfection, cells were 
split 1:10 and after an additional 24 hr were switched into selection medium consisting 
of the HEK-293 medium described above supplemented with 1.5 mg/mL Geneticin (Life 
Technologies, 10131-027) and maintained in this medium for 2 weeks to select for cells 
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expressing the plasmid of interest.  Stock cell cultures were maintained thereafter in 
HEK-293 media supplemented with 1mg/mL Geneticin.  Prior to harvesting, cells were 
plated in 15 cm dishes in HEK-293 media supplemented with 0.5 mg/mL Geneticin.   
All cell lines were treated prior to harvesting with ethanol (vehicle control, 0.08% 
v/v), 10 M HNE, or 50 M HNE.  The three treatments were prepared in serum-free 
media and placed on the cells for 1 hr at 37°C.  Cells were harvested with a cell scraper 
in the treatment medium and immediately centrifuged at 100 x g for 5 min at 4°C.  
Following this, the cell pellets were washed twice with ice cold phosphate buffered 
saline (PBS) and stored at -80°C until use. 
For the ASK protein colocalization imaging studies, ASK1, ASK2, and ASK3 
constructs were transiently co-transfected into HEK-293 cells using an Amaxa 
Nucleofector 2b (Lonza, Allendale, NJ) and the cell line Nucleofector Kit V (Lonza, VCA-
1003) using the manufacturer’s recommended HEK-293 electroporation protocol. 
 
RNA interference 
HEK-293 cells were plated in 10 cm dishes and transfected at 30% confluence 
using Lipofectamine RNAiMAX (Life Technologies, 13778-150) following the 
manufacturer’s suggested protocol.  Forty-eight hours after transfection, cells were split 
into two new 10 cm dishes.  Twenty-four hours later, cells were harvested, washed 
twice in PBS, and frozen at -80°C until use.  Anti-ASK1 Stealth siRNA duplexes with the 
following sequences: 5’-AAACAUUUCAGUAUGAAUGCCUUGG -3’ and 5’-
CCAAGGCAUUCAUACAAAAUGUUU-3’ (Life Technologies) specific for ASK1 (with no 
overlapping targeting on ASK2 or ASK3) were used at a concentration of 10 nM.  
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Negative control siRNA (Life Technologies, 12935-300) designed for use with medium 
GC content Stealth siRNA was used at the same concentration. 
 
Immunocytochemistry 
Cells were plated in a 6-well plate at a density of 100,000 cells per well with five 
12 mm glass coverslips in each well (Carolina Biological Supply, Burlington, NC, 
633029).  Three days later, the coverslips were washed once in PBS, fixed for 10 min at 
room temperature (RT) in 4% paraformaldehyde, blocked for 20 min at RT in 8% bovine 
serum albumin (BSA), washed twice with PBS and either stored at 4°C in PBS or used 
immediately for immunostaining.   
Fixed cells were imaged with either a Zeiss (Thornwood, NY) LSM510 META 
inverted confocal microscope (for the triple transfection) or a Zeiss Axioplan microscope 
equipped with an Apotome optical sectioning slider (for sub-cellular localization) and 
acquired images were analyzed using ZEN software (Zeiss).  For slides imaged with the 
Zeiss LSM510 META microscope, cells were permeabilized in 0.1% Triton X100 for 5 
min at RT, washed once with PBS, incubated with primary antibody in 1% BSA for 1 hr 
at 37°C in a humidified chamber, washed once with PBS, incubated with secondary 
antibody in 1% BSA for 30 min at 37°C in a humidified chamber, washed twice with 
PBS, and then mounted onto a slide with Prolong Gold (Life Technologies, P-36931).  
For slides imaged with the Zeiss Axioplan microscope, cells were permeabilized in 0.1% 
Triton X100 for 5 min at RT, washed three times with PBS, incubated with primary 
antibody in 1% BSA overnight at 4°C, washed six times with PBS, incubated with 
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secondary antibody in 1% BSA for 1 hr at RT, washed five times with PBS, and then 
mounted using Prolong Gold onto glass slides (VWR, 48312-003).  
  
Cell viability assays 
 Cells were plated in a 96-well plate at a density of 10,000 cells/well and allowed 
to grow for 24 hr.  Medium was then removed and replaced with 100 L/well of serum-
free DMEM containing the appropriate concentration of HNE and the cells were 
incubated at 37°C for 24 hr.  To measure cell viability, 10 L/well of WST reagent 
(Sigma, 11644807001) was added and the cells were incubated for 1 hr.  Absorbance 
readings then were taken at 450 nm and 650 nm with a Spectramax M4 
spectrophotometer (Molecular Devices, Sunnyvale, CA) according to the manufacturer’s 
protocol. 
 
Co-immunoprecipitation and western blotting 
Frozen cell pellets were lysed on ice in 500 L of NETN buffer (50 mM HEPES 
pH 7.5, 150 mM NaCl, and 1% Igepal supplemented with 10 L/mL of HALT [Life 
technologies, 78444] protease and phosphatase inhibitor), per 15 cm plate for 30 min 
with occasional inversion.  Lysates then were clarified by centrifugation at 10,000 × g for 
10 min at 4°C.  Protein in the clarified lysates was measured with the BCA assay (Life 
Technology, 23225).  Protein concentrations were adjusted to 2 mg/mL and 5 mg of 
total protein was added in a final volume of 2.5 mL to antibody beads pre-washed with 
NETN.  For each IP, a 50 L slurry of antibody-bead conjugate was washed twice with 1 
mL of NETN prior to incubation with protein lysates.  After addition of the protein lysate, 
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the beads were rotated at 4°C for 1 hr to allow for capture of the target protein.  
Following incubation, the beads were pelleted by centrifugation at 100 × g and the 
supernatant was discarded.  The beads were then washed twice with 1 mL of NETN 
buffer and the bound protein complexes were resuspended in 80 L of lithium dodecyl 
sulfate (LDS) sample buffer diluted 1:1 with NETN and supplemented with 50 mM 
dithiothreitol (DTT).  The samples were then frozen at -80°C until use.   
For western blot analysis, cell lysis and IP were carried out as described above.  
Gels were loaded with either 50 g of input protein or 5 L of IP and run for 50 min at a 
constant 180 V.  Proteins were then electrophoretically transferred to PVDF membranes 
(Life Technology, LC2002) using the BioRad (Hercules, California) wet transfer system 
(1703930) operated at a constant 300 mA current for 90 min at 4°C.  Membranes were 
blocked in a 1:1 mixture of Tris-buffered saline plus 0.05% Tween-20 (TBST) and 
blocking buffer (Rockland, Limerick, PA, MB-070) for 1 hr at RT while rocking.  Primary 
antibodies were diluted (1:2000 for tag antibodies, 1:1000 for protein antibodies, and 
1:750 for phospho antibodies) in the same buffer used for blocking, added to the 
membrane, and incubated at 4°C overnight with rocking.  After incubation, the 
membranes were washed three times with TBST, incubated with the appropriate 
secondary antibody diluted 1:10,000 in the same buffer used for the primary antibody, 
and allowed to rock for 30 min at RT.  The membranes were then washed three times 
with TBST, visualized using a LiCor Odyssey (Lincoln, Nebraska), and analyzed using 
Odyssey v3.0 software. 
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Size exclusion chromatography of ASK complexes 
Size exclusion chromatography (SEC) was performed as described previously 
(3) with minor modifications (see supplemental Fig. A10A).  For the IP-PRM assays, 6 
column runs were pooled and each target fraction (1-9) was immunopurified following 
the procedure described above with the exception of the buffer which consisted of the 
SEC buffer supplemented with 10 L/mL of HALT. 
 
Preparation of peptides for MS analyses 
Bead-bound protein complexes were eluted in LDS buffer and heated at 95°C for 
10 min prior to being loaded on a 10% Bis-Tris gel (Life Technologies, NP0301).  The 
gels were loaded with 35 L of each sample elution in alternate lanes (with a blank lane 
between sample lanes) and then were run at a constant 180 V for 3 min, after which the 
run was paused.  Each sample lane was then re-loaded with the remaining 35 L of 
each sample and the gel runs were resumed for an additional 7 min to complete loading 
of proteins into the gel.  Gels were then stained with Simply Blue safe stain (Life  
Technologies, LC6060) for 1 min in a microwave oven at maximum power and then 
allowed to destain in distilled water for 2-3 hr.  Each sample lane was cut as a single 
band and diced into ~1 mm cubes.  The gel pieces were placed into individual 
Eppendorf tubes and washed twice with 200 L of 100 mM ammonium bicarbonate 
(AmBic).  Samples were then reduced with 5 mM DTT in AmBic for 30 min at 60°C 
while shaking at 1000 rpm and then alkylated with 10 mM iodoacetamide in AmBic for 
20 min in the dark at RT.  Excess blue dye was then removed with three 200 L washes 
in 50 mM AmBic:acetonitrile (1:1, v/v) and the gel pieces were dehydrated in 100% 
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acetonitrile.  The gel pieces were rehydrated in 200 L of 25 mM AmBic with 300 ng of 
trypsin gold (Promega, Madison, WI) per sample and placed in a 37°C incubator for 16 
hr.  Peptides were extracted from the SDS gel with three 20 min incubations in 200 L 
of 60% acetonitrile / 40% water containing 1% formic acid and evaporated to dryness in 
vacuo.  The peptides were resuspended in 30% acetonitrile / 70% water containing 
0.1% formic acid and stored at -80°C until use.  Labelled peptide standards for 
quantitative analyses (see below) were spiked in at this reconstitution step. 
 
Mass spectrometry 
 Shotgun analyses of the single gel fraction samples were carried out on a Q 
Exactive Plus mass spectrometer (ThermoFisher Scientific, San Jose, CA) equipped 
with a Proxeon nLC1000 LC (ThermoFisher Scientific) and a Nanoflex source 
(ThermoFisher Scientific).  Peptide mixtures were evaporated in vacuo and 
resuspended in 2% acetonitrile / 98% water containing 0.1% formic acid and loaded 
onto an 11 cm long column with a 75 m internal diameter (New Objective, Woburn, 
MA, PF360-75-10-N-5) packed with 3 m particle size and 120 Å pore size ReproSil-Pur 
C18-AQ resin (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) and separated 
over a 100 min gradient with a mobile phase containing aqueous acetonitrile and 0.1% 
formic acid programmed from 2-5% acetonitrile over 5 min, then 5 to 35% acetonitrile 
over 80 min, then 35-90% acetonitrile over 5 min, followed by 10 min at 90% 
acetonitrile, all at a flow rate of 300 nL/min.  A single MS1 scan from m/z 300-1800 at 
70,000 resolution with an automatic gain control (AGC) value of 3e6 and max injection 
time of 64 msec was recorded as profile data.  A top 12 method was used, whereby the 
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12 most intense precursors were automatically chosen for MS2 analysis and a dynamic 
exclusion window of 20 sec was employed.  For each MS2 scan, a resolution of 17,500, 
an AGC value of 2e5, a max injection time of 100 msec, a 2.0 m/z isolation window, and 
a normalized collision energy of 27 was used and centroid data were recorded. 
 PRM assays were also performed on the ThermoFisher Scientific Q Exactive 
Plus instrument and LC system described above. For PRM analyses, peptides were 
separated over a 70 min gradient: from 2-5% acetonitrile over 5 min, then 5 to 35% 
acetonitrile over 50 min, then 35-90% acetonitrile over 5 min, followed by 10 min at 90% 
acetonitrile, all at a flow rate of 300 nL/min.  The PRM method consisted of an MS1 
scan at 17,500 resolution with an AGC value of 3e6, max injection time of 64 msec, and 
scan range from m/z 380-1500 recorded as profile data.  This was followed by 14 
targeted MS2 scans at a resolution of 17,500 and with an AGC value of 5e5, a max 
injection time of 80 msec, a 0.5 m/z isolation window, a fixed first mass of 150 m/z, 
normalized collision energy of 27, and recorded as profile data.  The targeted-MS2 
methods were controlled with a timed inclusion list containing the target precursor m/z 
value, charge, and a 3 min retention time window that was determined from prior 
analyses of synthetic peptide standards as described (27).  Lists of all peptides targeted 
for PRM analysis are given in Tables S1-S3. 
 
Targeted protein quantitation  
Two targeted protein analysis methods were employed in this study, the labelled 
reference peptide (LRP) and stable isotope dilution (SID) methods. The first relied on 
normalization of each unlabelled target peptide to a heavy isotope labelled peptide 
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standard called the labelled reference peptide (LRP) for relative quantitation (27).  
Three LRP standards (GYSFTTTAER^, AAQGDITAPGGAR^, and 
APLDNDIGVSEATR^) were purchased from New England Peptide (Gardner, MA) at 
>98% purity and quantified by amino acid analysis.  For all LRP assays, the heavy 
peptide was spiked in at 2.5 fmol/L to enable normalization. 
The second method was stable isotope dilution (SID), whereby a heavy isotope 
labelled analog of each target peptide was spiked into each sample to allow for absolute 
quantitation and stoichiometry determination.  Light and heavy peptide pairs for 26 
peptides representing 26 proteins (Table S14) were purchased from New England 
Peptide.  Each heavy peptide was synthesized with a terminal lysine or arginine that 
was uniformly labelled with C13 and N15 resulting in a mass shift of +8 Da for lysine and 
+10 Da for arginine.  Heavy labelled peptides were of >99% isotopic purity and >98% 
peptide purity as determined by HPLC-UV and LC-MS analysis.  Absolute concentration 
of the heavy labelled peptides was determined by amino acid analysis.  Eight-point 
reverse calibration curves (Fig. A5) were generated for each peptide pair by spiking in a 
constant level of 2.5 fmol/L of light peptide and varying the amount of heavy peptide 
from a high value of 100 fmol/L to a low value of 0.0064 fmol/L.  Assay linearity 
across all concentration points was assessed and an equation for determining the 
analyte concentration using the peak area ratio of light/heavy isotopologues was 
defined using QuaSAR (28), which was implemented through the Skyline interface as 
described (29).  The lower limit of quantitation (LLOQ) for each peptide was defined as 
the lowest point on the calibration curve with a coefficient of variation <25% across 
three technical replicates.  The lower limit of detection (LLOD) was defined as one-third 
91 
 
of the LLOQ.  For all SID assays, the heavy peptide was spiked in at 2.5 fmol/L to 
enable normalization and absolute quantitation.  Data below the LLOQ was excluded 
from all analyses. 
 
Data analysis 
 Thermo .raw datafiles from shotgun LC-MS/MS runs were converted to mzml 
format using Proteowizard version 3.0.5211 (30).  The mzml files were searched using 
MyriMatch version 2.1.132 (31), Pepitome version 1.0.42 (32), Comet version 2014.01.1 
(33), and MS-GF+ version 9517 (34) against the human Refseq version 54 database 
(Sep 25, 2012; 34,590 entries).  A semi-tryptic search was employed with a maximum of 
four missed cleavages allowed.  A fixed carbimidomethyl modification on Cys, a variable 
oxidation on Met, and a pyro-glu on Gln were allowed with a maximum of 3 dynamic 
modifications per peptide with a precursor ion tolerance of 10 ppm and a fragment ion 
tolerance of 20 ppm.  A target-decoy search was employed using a reverse sequence 
database to allow calculation of FDR for peptide-spectrum matches (35).  Protein-level 
FDR was calculated by dividing the number of reverse sequence proteins identified by 
the total number of proteins identified, multiplying by two and converting to a percent.  
All search result files were parsimoniously assembled in IDPicker 3 version 3.1.643.0 
(36).  SAINTexpress version 3.1.0 (37, 38) was used with the Spotlight (39) interface to 
identify non-specific ASK protein interactions detected by the IP analyses.   
 PRM runs were designed and analyzed using Skyline (40) and three transitions 
per peptide were used for quantitative analyses.  For LRP quantitation, the summed 
peak areas of all three transitions of the target peptides were normalized against those 
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of a heavy labelled peptide that was spiked into all runs at a constant concentration to 
correct for run-to-run variation caused by the instrument. Of the three LRP peptide 
standards spiked into all samples, the one used for normalization within each 
experimental system (e.g., ASK1-TAG cells, ASK2-TAG cells, etc.) had the lowest 
coefficient of variation for that system.  LRP-normalized peak areas were further 
corrected for variances in protein concentration due to IP efficiency differences across 
experiments using an internal reference peptide (IRP) (41) from the ASK bait protein. 
Thus, all peptide results reported from the PRM assays are ratios of the amount of peak 
area for the analyte peptide divided by the peak area for the LRP peptide; this ratio was 
then divided by the peak area for the light SID peptide from the ASK bait protein.  This 
final correction step minimizes measurement variation due to differing efficiencies of 
protein capture in each IP. 
Peptides targeted for SID measurements were first normalized to the appropriate 
heavy labelled standard and then further normalized to an IRP as described above.  
Specifically, the peak area for the light target peptide was divided by the peak area of 
the corresponding heavy peptide; this ratio was then further divided by the light SID 
peptide signal for the ASK bait protein.  This final correction step minimizes 
measurement variation due to differing efficiencies of protein capture in each IP.  For 
stoichiometric analysis, absolute molar amounts of each peptide present in the IP were 
calculated using the standard curve and these were expressed as a percent of total 
ASK bait protein present in order to estimate the stoichiometry of the complex. 
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Experimental Design and Statistical Rationale 
For initial data-dependent LC-MS/MS studies to compare IP methods, three 
biological replicate samples were analyzed for each of the IP methods, together with 3 
negative control replicates.  Similarly, for data-dependent LC-MS/MS analyses of the 
composition of ASK signalosome complexes, three biological replicate samples were 
analyzed for each of the IP methods, together with 3 negative control replicates.  These 
sample sizes and datasets enable confident estimates of measurement variation and 
protein complex composition based on spectral count data (42) and application of the 
SAINT algorithm and software (37, 38).  
To evaluate the dynamics of ASK signalosome changes in response to HNE 
electrophile stress, four biological replicate samples were performed for each cell line 
(five for ASK1-TAG).  For these ASK signalosome dynamics experiments, 24 control 
replicates were prepared and each was run as two technical replicates interspersed 
between the IP samples to control for both non-specific binding and any potential 
carryover.  The 48 control PRM analyses were divided among the 4 cell lines based on 
run order and all technical replicates were treated as independent for statistical testing.  
For PRM studies of the effects of ASK1 knockdown, four biological replicates and six 
controls were prepared and run as described above.  For studies of the composition of 
ASK signalosome fractions prepared by size exclusion chromatography, two biological 
replicates were performed for each sample along with one negative control replicate 
that was run as two technical PRM injections as described above.  These sample sizes 
were chosen to be sufficiently large enough to document measurement variation and 
assess significance of differences with the tests enumerated below.   
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Concentration-dependent differences in protein-protein interactions with the bait 
protein were assessed using both the two-tailed Jonckheere-Terpstra test (43, 44) to 
identify trends in the concentration-response relationships and the Kruskal Wallis test 
(45) with Dunn’s post-hoc testing (46) to identify significant differences in the means of 
each concentration point via the DescTools package in R.  The Wilcoxon rank sum test 
(47) was used to determine if the peptides targeted were significantly enriched over the 
negative control IPs.  These non-parametric test methods were chosen as the IP data in 
this study was found to be non-normally distributed.  All statistical tests were carried out 
in the R environment.  Raw data files can be downloaded at: 
ftp://MSV000079399@massive.ucsd.edu and processed Skyline files can be 
downloaded at https://panoramaweb.org/labkey/Liebler_ASK.url. 
 
Results 
 
ASK-expressing HEK-293 cell lines 
 I first generated cell lines that express epitope-tagged versions of ASK1 and the 
related MAP3Ks, ASK2 and ASK3.  ASK2 was chosen as it is a known interacting 
protein of ASK1 (48-53).  ASK3 (54, 55) is a highly similar MAP3K that I identified as a 
potential ASK1-interacting protein in a pilot shotgun study of ASK1 (data not shown). 
HEK-293 cells were chosen as they have been used for much of the published ASK1 
research to date and are easily transfected.  Because of the low endogenous 
expression of ASK1 and the lack of suitable antibodies for immunoprecipitating 
endogenous ASK2 and ASK3, I chose to clone a unique tandem affinity purification tag 
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(TAG) in-frame with each of the ASK genes (Fig. II-1A). These tags allowed us to 
conduct very clean immunofluorescent assays and highly efficient and specific 
immunopurifications.  I transfected each of the ASK-TAG constructs into separate HEK-
293 cells, thus creating three different cell lines, each stably expressing one of the 
tagged ASK proteins.  I confirmed the transfections by Western blotting (Fig. II-1B).   
I further confirmed that the tagging and overexpression of these three proteins 
did not cause aberrant sub-cellular localization via immunocytochemistry staining.  
Overexpressed and endogenous ASK1 both showed cytosolic and perinuclear 
localization (Fig. II-1D & E), consistent with published literature (56-58).  In addition, no 
aberrant aggregation of the overexpressed proteins in the three cell lines was detected 
(Fig. A1).  To verify the function of ASK1-TAG in transfected cells, I treated the cells 
with HNE (Fig. A2).  HNE activated the ASK1 MAPK pathway in a time- and dose-
dependent fashion, as shown by Western blot, which detected increased activating 
phosphorylation of ASK1 (pT838), as well as increased phospho-JNK and phospho-p38 
staining, all of which are consistent with previous reports (5, 25). 
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 Figure II-1.  ASK-TAG cell lines.  (A) Design of tandem-tagged ASK proteins. 
(B) Western blots showing expression of ASK proteins and their epitope tags in HEK-
293 cells.  (C) Western blots demonstrating the tandem-IP procedure for each of the 
ASK-TAG proteins. (D & E) Immunocytochemistry of HEK-293 parental (D) and ASK1-
TAG (E) cells showing similar localization of ASK1 (magenta) in both cell systems.  Blue 
= DAPI, Green = Tubulin. 
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Shotgun LC-MS/MS analysis of ASK1-interacting proteins 
I optimized a tandem-IP method to minimize potential non-specific interactions 
through the sequential IP steps (Fig. II-1C).  While a tandem IP can reduce non-specific 
interactions, it can also fail to detect true interactions that do not survive both capture 
steps.  I performed an IP method comparison using the ASK1-TAG cells, as ASK1 has 
the largest number of reported interactors among the three ASK proteins.  I tested three 
different purifications using the FLAG and/or HA tags: a) anti-FLAG IP, followed by 
FLAG peptide release and recapture with anti-HA, b) anti-FLAG IP, and c) anti-HA IP.  
Each IP was performed in triplicate along with three negative control IPs consisting of 
untransfected HEK-293 cells. After shotgun LC-MS/MS analyses of the IPs, the data 
were searched and assembled together at a protein FDR of 0.88%.   
The complete list of protein identifications from this experiment are provided in Table 
S4.  Across all three IP methods, I identified 28 out of 94 (30%) previously reported 
ASK1-interacting proteins.   
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Figure II-2.  Comparison of ASK1 IP methods.  Three IP methods for ASK1 were 
analyzed by data-dependent shotgun MS and the proteins identified in each IP were 
scored by SAINT.  The heat map shows SaintScores for all proteins that were at least 
0.4 in one IP method.  The proteins listed in the Venn diagram are those with a high-
confidence SaintScore of at least 0.8.  Proteins listed in bold are previously reported 
ASK1-interacting proteins. 
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I then applied the SAINT algorithm to determine which of the identified proteins in 
each IP experiment were best supported by the spectral count data as specific binding 
partners of the ASK proteins.  SAINT uses the negative control data to generate a 
probability score for each protein present in a purification, which allows for a 
comparison of the robustness of each IP method employed for ASK1.  The SAINT 
scores for all proteins identified in each IP are provided in Tables S5-S7.  The HA IP 
generated the most interactions with a high SaintScore, whereas the FLAG IP 
generated the most identified interactions overall, and the tandem IP generated the 
fewest interactions (Fig. 2).  However, application of a SAINTScore threshold of ≥0.8 
yielded only 32 proteins that passed the filter (Venn diagram in Fig. II-2), of which only 
four were previously reported as ASK1-interactors (bold proteins in Venn diagram).  
Three of the reported interacting proteins were identified in all three IP methods; of 
these, ASK2 is a well-documented ASK1 interactor, whereas ATAD3A and NACC1 
were only recently reported in another AP-MS study (53).   
I decided to further examine the putative ATAD3A interaction, because it (along 
with ATAD3B) represented the highest number of spectral counts for ASK1 interacting 
proteins other than ASK2.  I confirmed the interaction between ASK1 and both ATAD3A 
and ATAD3B in the ASK1-TAG cells (Fig. A3A) by co-IP Western blot analysis, but I 
was not able to confirm this interaction in the HEK-293 cells (Fig. A3B).  I also could not 
detect the interaction between ASK1 and ATAD3A by co-IP and Western blotting in 
another cell line (RT4 cells) with a higher endogenous level of ASK1 expression (Fig. 
A3B).  I therefore concluded that the apparent ASK1-ATAD3A/ATAD3B interaction was 
an artifact of the ASK1-TAG model. 
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Interaction between ASK1, ASK2, and ASK3 
Another protein of interest identified in all three IP methods was ASK3 
(MAP3K15).  I had previously identified this protein as a potential ASK1-interactor in a 
preliminary shotgun screen of ASK1-expressing cells and the presence of ASK3 in all 
three IP methods seemed to support this conclusion.  To further investigate the 
association of the three ASK proteins (ASK1, ASK2, and ASK3), I transiently 
electroporated all three proteins into HEK-293 cells in order to perform co-localization 
studies.  As can be seen in Fig. II-3A, all three of the ASK proteins show similar 
subcellular distributions and co-localization (white color in the Merge panel of Fig. II-3A). 
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Figure II-3.  Validation of ASK protein interactions.  (A) ICC imaging of all three ASK 
proteins co-transfected into HEK-293 cells shows co-localization (white color in right-
most panel).  (B) Co-IP western of ASK2 and ASK3 interacting with transiently 
expressed ASK1.  (C) PRM analysis of immunopurified endogenous ASK1 complexes 
from cells treated with non-targeting (left) and ASK1-targeting (right) siRNA shows a 
decreased amount of ASK1 purified and a concomitant decrease in ASK2 and ASK3. 
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I also performed a transient transfection of only ASK1 and used co-IP and 
Western blotting to detect ASK2 and ASK3 association with overexpressed ASK1 (Fig 
II-3B).  The available antibodies for ASK2 and ASK3 did not enable sufficiently sensitive 
detection for co-IP Western analysis at their endogenous expression levels in HEK-293 
cells.  Instead, I used a parallel reaction monitoring (PRM) targeted MS assay to 
demonstrate the association of all three ASK proteins in an endogenous ASK1 IP (Fig 
II-3C).  Furthermore, I performed siRNA knockdown of endogenous ASK1 in HEK-293 
cells (Fig. A4A) and showed with PRM analysis that decreasing the amount of 
expressed ASK1 also decreased the amount of associated ASK2 and ASK3 in co-IP 
analyses (Fig. II-3C).  In addition, I monitored many of the previously reported ASK1-
interacting proteins, but saw no other proteins that followed the same trend seen with 
ASK2 and ASK3 (see Fig. A4B&C and Tables S8-S9).  This series of experiments 
confirmed the previously reported association of ASK2 with ASK1 and identified ASK3 
as a new ASK1-interacting protein.  Furthermore, the siRNA knockdown experiment 
suggested a proportional interaction among the three ASK proteins. 
 
Targeted MS analysis of ASK1-interacting proteins 
My inability to detect previously reported ASK1-interacting proteins in data-
dependent LC-MS/MS analyses of co-IPs suggested that they were present at relatively 
low levels compared to the overexpressed ASK1 and that more sensitive targeted 
methods would be required to detect these proteins.  Thus, I re-analyzed the same co-
IP samples described above with a PRM assay, which targeted 66 previously reported 
ASK1-interacting proteins listed in Table S1.  For these experiments I used the LRP 
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method, which employs a single heavy isotope labelled peptide as a normalization 
standard for all target peptides in the analysis and provides a cost-effective means to 
quantitatively compare abundance of larger numbers of proteins between samples (27).  
This LRP-PRM assay was thus used to detect significant enrichment of the target 
proteins in ASK1-TAG co-IPs. 
These analyses detected 61 of the 66 targeted ASK1-interacting proteins (92%) 
(Tables S10-S13).  Significant enrichment was defined as either a) detection in at least 
2 of 3 biological replicates for proteins not detected in the control samples or b) by a 
significant (p≤0.05; Wilcoxon rank test) and at least 3-fold enrichment over control 
samples (Fig. II-4).  Of the sixty-two enriched proteins, I detected 60 in the HA IP while 
only observing 29 in the FLAG IP and 6 in the tandem IP.  These results thus confirmed 
the association of most previously reported ASK1 interacting proteins; albeit at levels 
that appeared to be much lower than ASK1.  
 
  
104 
 
 
Figure II-4. Comparison of ASK1 IP methods by targeted proteomics. PRM 
analyses of the same samples as Fig. 2 identified 61 out of 66 reported ASK1-
interacting proteins targeted.  Sixty of those proteins were detected in the HA IP at an 
enriched level over control.  Black signifies that the protein was not detected, yellow that 
the protein was detected but was not enriched, and red that the protein was detected 
and enriched over background. 
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Targeted assay strategy for ASK1 complex dynamics and stoichiometry studies 
Because PRM analyses enabled detection of many previously reported ASK1-
interacting proteins in the co-IP analyses, I pursued a targeted analysis strategy for 
studies of the dynamics of ASK signalosome components in response to HNE 
electrophile stress and to further characterize the stoichiometry of ASK1 interaction with 
other putative signalosome protein components. A targeted analysis strategy employing 
a combination of LRP-PRM and SID-PRM assays for these studies is represented in 
Fig. II-5.  I employed the LRP-PRM approach to target 94 proteins, including the 68 
targeted in the co-IP analyses described above, as well as additional proteins 
hypothesized to have ASK1 interactions.  These proteins and the targeted peptides and 
precursor m/z values are listed in Table S2.  Because normalization to the LRP 
standard provides ratios for each peptide (peak area for peptide/peak area for LRP 
standard), these values can be used for relative quantitation between HNE exposures 
for the dynamics experiments.   
For measurements of stoichiometry of ASK1-interacting proteins, I required 
absolute quantitation and therefore performed SID-PRM analyses for 26 peptide targets 
(Table S3) corresponding to a subset of 26 ASK1-interacting proteins identified as 
significant interactors in the co-IP experiments above. Calibration curves for all 26 
peptides are shown in Fig. A5 and the specific features of each assay (target peptides, 
transitions, LLOD, LLOQ, linearity) are presented in Table S14.   
These two quantitative strategies were applied simultaneously in the same study 
of the dynamics of ASK signalosome proteins in response to HNE treatment.  The 
combined LRP-PRM and SID-PRM analysis targeted 254 peptide precursors from the 
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94 proteins, three LRP standard peptide precursors, and 26 stable isotope labelled SID 
standard peptide precursors.  For LRP-based quantitation, multiple peptides were 
targeted for most of the proteins.  For SID-based quantitation, a single peptide per 
protein and its heavy isotopologue standard were measured. Quantitative comparisons 
of each protein between conditions were based on the data for a single peptide per 
protein generated either by LRP (normalized ratio) or by SID (molar quantity) 
measurements.  For the 26 proteins for which SID measurements were possible, these 
were used in preference to LRP measurements.  For proteins for which multiple 
peptides were targeted for LRP measurements, the one with the highest average peak 
area across all IPs was used for quantitative comparisons.  
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Figure II-5.  ASK PRM assay development.  An LRP-PRM assay was used to target 
reported ASK1 complex members in the samples previously analyzed by shotgun MS.  
For the subsequent assays examining ASK complex dynamics, I added additional 
protein targets and developed an expanded LRP-PRM (see text for discussion).  Of the 
94 proteins in the expanded assay, 26 were selected for concurrent SID analyses with 
the addition of stable isotope-labelled standards for use in the complex stoichiometry 
study. 
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Dynamic changes in ASK signalosome composition in response to HNE  
 I performed WST cell death assays to determine the HNE concentrations to use 
for studies of ASK1 protein interaction dynamics.  All three ASK-overexpressing cell 
lines and the non-transfected HEK-293 cell line yielded a similar EC50 value 
(approximately 10 M) for HNE (Figure A6A).  The effectiveness of this HNE 
concentration in triggering electrophile stress was confirmed by Western blot analysis of 
the activating Thr838 phosphorylation of ASK1 in the ASK1-TAG cell line, which 
showed a much higher level of activation at 20 M than 5 M (2-fold above and below 
the EC50 value, respectively) (Fig. A6B).  These assays, along with evidence of maximal 
ASK1 MAPK pathway activation after 1 hr of treatment (Fig. A2), led us to select a 
treatment time of 1 hr with three concentrations: 0 M HNE (ethanol vehicle control - 
below EC50), 10 M HNE (EC50), and 50 M HNE (above EC50). 
 I treated the four cell lines with HNE in quadruplicate (quintuplicate for ASK1-
TAG) at each concentration and confirmed the success and uniformity of the IPs by 
Western blotting (Fig. A7A) prior to running the PRM analyses of the corresponding 
samples.  I first determined the amount of the ASK1, ASK2, and ASK3 proteins present 
in IPs from ASK1-TAG, ASK2-TAG, and ASK3-TAG cells, as well as from non-
transfected control HEK-293 cells (Fig. A7B).  ASK1 and ASK2 were both purified at 
higher amounts from their respective cell lines, whereas amounts of immunoprecipitated 
ASK3 from ASK3-TAG cells and ASK1 from non-transfected cells were over an order of 
magnitude lower.   
 To detect HNE-induced changes in the ASK protein complex composition for 
each cell line, I employed two different strategies.  First, I compared the means of the 
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LRP- and SID-normalized peak areas for each detected peptide at each concentration 
using the Kruskal-Wallis test with a Dunn’s post-test.  Differences between the means 
are indicated by blue connecting bars in the graphs in Figure II-6A and B.  I also 
performed a Jonckheere-Terpstra (JT) test to detect trends in response consistent with 
a concentration-dependent relationship. Figure II-6A and B depict measurements of 
NACC1, YWHAG, PSMC2, and HSP90AB1, all of which have significant (p≤0.05) JT 
test values, indicating that these four peptides exhibit increased abundance with 
increasing HNE concentration.   
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Figure II-6.  ASK complex dynamics in response to HNE treatment.  (A & B) Four 
proteins that exhibited a positive concentration-response relationship to HNE in the 
ASK1-TAG cells (A) and the ASK2-TAG cells (B).  (C) Summary of all the peptides 
detected in the ASK complex dynamics study.  Black signifies that the peptide was not 
detected in the IP; yellow indicates that the peptide was detected, but did not change 
significantly in response to HNE; and red indicates that the peptide was detected, was 
enriched above the negative control, and exhibited a significant HNE-dependent change 
for at least one treatment concentration. 
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As a further test of specificity, I performed Wilcoxon rank sum tests between 
each treatment condition and the negative control to access whether or not the peptide 
was part of a true protein-protein interaction with the bait protein or if it was merely non-
specifically purified.  A red mean bar was used to denote peptides that were enriched 
over the negative control at that concentration point with either a Wilcoxon p-value ≤ 
0.05 or detection in at least half of the replicates at a given concentration point and no 
detection in any of the negative control replicates. 
Figure II-6C summarizes the findings of the concentration-response relationships in the 
ASK complex in all four cell lines.  I detected 79 peptides corresponding to 44 proteins 
in at least one of the cell lines.  The ASK1-TAG cells had the largest number of 
significant changes in protein complex composition (red bars), whereas the ASK2 and 
ASK3 cell lines only had a few each.  In total, 15 proteins exhibited concentration-
dependent shifts in association with the three ASK proteins and 14 of these were 
observed with ASK1 alone.  Furthermore, because of the low expression level of ASK3 
in the ASK3-TAG cell line, the majority of the detected peptides were not significantly 
enriched over the negative control samples.  Measurements in non-transfected HEK-
293 cells expressing endogenous ASK1 had no significantly changing ASK-interacting 
proteins in response to HNE, probably because the low abundance of ASK1 made it 
difficult to quantify interactors. Data for the individual protein measurements 
summarized in Figure II-6C are presented in Figures A8 and A9; the normalized protein 
measurements with statistical test results can be found in Tables S15-S19. 
 A well-known caveat with AP-MS studies is that artifactual protein-protein 
associations may be observed in studies with overexpressed, epitope-tagged proteins. 
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To address this possibility for the 14 proteins found to exhibit a dynamic association 
change with ASK1-TAG in response to HNE treatment, I measured levels of these 
proteins in the ASK1 IPs from the HEK-293 cells.  Most (11 of 14) were detected in the 
endogenous ASK1 IPs at a higher level than in the negative control IPs (Figure A10).  
Those 112 proteins thus are significantly associated with ASK1 at endogenous levels 
and the association is independent of an epitope tag.  Moreover, if these associations 
had been driven simply by overexpression of ASK1-TAG protein, association 
differences upon HNE treatment would not be expected.  The failure to observe this 
HNE-dependent dynamic in untransfected cells may reflect the difficulty of measuring 
changes in association at the low abundance levels of endogenous ASK1. 
 
Analysis of ASK signalosome populations prepared by size exclusion chromatography 
Although several proteins displayed concentration-dependent changes in 
response to HNE treatment, there were fewer changes than might be anticipated from 
the ASK1-signalosome remodeling hypothesis (2, 3).  I hypothesized that some of the 
dynamic shifts in the ASK complex composition could have been masked by a 
potentially heterogeneous mixture of pre- and post-activation ASK signalosome 
complexes.  ASK1 has been reported to undergo a shift in complex size upon activation 
by oxidants and thereby change from a ~1500 kDa pre-activation complex to a much 
higher molecular weight post-activation complex (3). 
To assess this possibility, I repeated the size exclusion chromatography (SEC) 
fractionation of the ASK complex as described by Ichijo and colleagues (3) with minor 
modifications (Fig. A11A).  My measurements suggested a minimum complex size of 
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approximately 669 kDa, which is consistent with the analysis by Ichijo and colleagues 
(21).  However, I did not observe a shift in the distribution of ASK1 or phospho-ASK1 
across SEC fractions (Fig. A11B&C).  PRM analysis of ASK1, ASK2, and ASK3 in IPs 
from SEC-fractionated ASK1 complexes revealed a similar distribution of the ASK 
proteins as was seen for ASK1 in the Western blot analyses (Fig. A11D). 
 
ASK protein complex stoichiometry 
 SID-PRM measurements in the ASK signalosome dynamics study provided 
absolute quantitative estimates of ASK1-interacting proteins in the IPs.  I used these 
measurements to estimate protein stoichiometry relative to bait protein as has been 
done for other systems (59-62).  The apparent stoichiometry varied somewhat 
depending on the cellular context.  In the ASK1-TAG cell co-IPs (Fig. II-7A), ASK2, 
ASK3, 14-3-3 proteins (YWHAQ, YWHAB, YWHAH, and YWHAE measured collectively 
by a common peptide), PARK7, PRDX1, and USP9X were present at a few percent of 
the level of ASK1.  Analyses of the ASK2-TAG cell co-IPs (Fig. II-7C) yielded data 
similar to the ASK1-TAG IPs, with ASK1, ASK3, 14-3-3 proteins, PARK7, PRDX1, and 
USP9X present at a few percent of the level of ASK2.  Interestingly, measured levels of 
some of the interacting proteins appeared to increase with increasing HNE treatment 
concentration.     
In co-IPs of endogenous ASK1 from untransfected cells (Fig. II-7B), the 
stoichiometry of ASK2 relative to ASK1 was approximately 1:1 and that of 14-3-3 
proteins to ASK1 was approximately 0.5:1.  The other proteins measured at low levels 
in co-IPs of ASK1-TAG and ASK2-TAG were also present at less than 10% of 
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endogenous ASK1 and PRDX1 was not detected as a partner of endogenously 
expressed ASK1.  
ASK3-TAG co-IPs expressed a level of ASK3 lower than that of endogenous 
ASK1 in co-IPs from untransfected cells (Fig. II-S7B) and 14-3-3 proteins and PRDX1 
were present in stoichiometries of approximately 0.5:1 and 0.7:1 relative to ASK3, 
respectively (Fig. II-7D).  Other detected interactors were present at levels less than 
10% of ASK3.  
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Figure II-7. ASK1 complex stoichiometry.  Apparent stoichiometry of the ASK 
complexes present in each cell relative to the ASK bait protein component as assessed 
by SID-PRM measurements.  For ASK1-TAG (A), ASK2-TAG (C), and ASK3-TAG (D), 
all detected proteins were calculated relative to the overexpressed protein in each cell 
line.  For the endogenous ASK IP from non-transfected cells (B), all detected proteins 
were calculated relative to endogenous ASK1. 
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Discussion 
 
 ASK1 is thought to be regulated by a large multiprotein complex that changes 
composition dynamically in response to oxidative stress.  The candidate membership 
list—ASK1 and its 90 reported interacting proteins—together would be too large to 
comprise a signalosome complex of the reported 1,500 kDa size (3).  I therefore asked 
which members of this candidate list are constitutively bound to ASK1 and how does 
this repertoire of interacting molecules change upon activation of the ASK1 pathway by 
HNE electrophile stress.  I first confirmed ASK1 interactions with most of the reported 
interactors with shotgun and targeted MS analyses.  Using targeted PRM assays, I also 
identified 14 proteins that demonstrated dynamic shifts in their association with ASK1 
under stress. Using precise SID-based measurements, I next provided the first ever 
quantitative examination of the ASK complex.  I detected ASK2 as a 1:1 stoichiometric 
binding partner of ASK1 and several 14-3-3 proteins as ASK1 interactors with a 
collective stoichiometry of approximately 0.5:1. ASK3 and several other proteins 
exhibited stoichiometries of 0.1:1 or lower.  These stoichiometries were consistent 
between ASK1-TAG and ASK2-TAG complexes and immunoprecipitates of 
endogenous ASK1.  Moreover, the complex size calculated from the stoichiometry 
measurements is consistent with SEC analyses of ASK1 complexes.    The data 
suggest a core ASK signalosome consisting of ASK1, ASK2 and 14-3-3 proteins, which 
interacts with a variety of other proteins to mediate MAPK activation and possibly other 
diverse signaling events.     
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 Most previous studies of the ASK1 multiprotein complex have been done using 
IP/Western blot methods to identify binary interactions, but these methods provide little 
insight into the composition and dynamics of multiprotein complexes.  Shotgun 
proteomics analyses have been extensively used to inventory members of multiprotein 
complexes and enable unbiased discovery of novel components.  Targeted proteomics 
assays can provide quantitative information that enables insights into complex function.  
Here I used LRP- and SID-PRM assays to examine the compositional changes of the 
ASK signalosome in response to HNE stress.   
These two targeted quantitation approaches are complementary in the way they 
were applied here.  The LRP method requires only a single labeled reference standard 
and thus offers the most cost-effective approach to a targeted survey of 90 candidate 
binding partners.  However, the method is potentially subject to ionization suppression 
and interferences due to the lack of labeled standards for all analytes (29).  Thus, my 
use of SID-PRM analyses of a single peptide for each of 26 candidate ASK1-interacting 
proteins enabled highly precise quantitation, which was sufficient for estimates of 
complex stoichiometries.  Although measurement of a single peptide per protein could 
be subject to interference by unanticipated protein modification or cleavage, all of the 
SID measurement trends were consistent with multiple estimates from the LRP method 
with the same samples. 
I identified 14 proteins that showed an increased association with ASK1 in 
response to HNE, including two HSP genes (HSP90AA1 and HSP90AB1), two 
proteasome components (PSMC1 and PSMC2), several 14-3-3 family proteins 
(YWHAE, YWHAG, YWHAH, YWHAQ, and YWHAZ), and the antioxidant protein 
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PRDX1.  Most of these proteins were also found to be enriched (though not dynamic) in 
ASK1 IPs over the negative controls in the endogenous HEK-293 cell line, which lends 
further support to the validity of these proteins as components of a dynamic ASK 
multiprotein complex.  This precise, multiplexed quantitative assessment of component 
dynamics would be impossible with IP/Western methods.  
 An important element of my approach is the use of complementary epitope-
tagged overexpression cell models for ASK proteins, which provided reinforcing data on 
the ASK signalosome.  The proteins detected in all of the ASK-TAG cell line IPs were 
similar (Figs. II-6 & II-7), especially those analyzed by SID-PRM in the ASK1-TAG and 
ASK2-TAG cell lines with regard to both the proteins identified and the trends in 
association observed.  The composition of ASK IPs from both cell lines was also 
remarkably similar to that of native ASK IPs from untransfected cells (compare Figs. II-
7A & II-7C with Fig. II-7B).  SID-PRM data from the endogenous ASK1 IP revealed an 
approximately 1:1:0.5 stoichiometry of ASK1:ASK2:14-3-3 proteins.  Even though ASK1 
and ASK2 levels were much higher in the overexpressing cell models, the SID-PRM 
analyses of the ASK2/14-3-3 binding partners in the ASK1-TAG complex and ASK1/14-
3-3 binding partners in the ASK2-TAG complex revealed stoichiometries similar to those 
in native ASK1 complexes from untransfected cells.  Additionally, by overexpressing 
ASK1 and ASK2, I were able to detect dynamic protein-protein associations that could 
not be observed at endogenous ASK1 expression levels, likely due to the approximately 
40-fold lower expression level of the ASK proteins in untransfected cells (Fig. A7).  
Thus, examining a multiprotein complex at multiple expression levels can provide 
insights that would otherwise be missed. 
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 One of the disadvantages of overexpression systems is that they can generate 
false-positive associations.  In the shotgun analysis of ASK1-TAG IPs, I identified the 
previously reported ASK1-interacting protein ATAD3A (53) as a putative ASK1 
interactor by all three IP methods.  I then attempted to validate this interaction by 
Western blotting and was able to do so in the overexpressing cell line, but not in two 
different non-transfected systems (Fig. A3).  This suggested that the interaction 
between ATAD3A and ASK1 may be mediated by the presence of the affinity tags.  The 
previous study by So et. al. reporting an ASK1-ATAD3A interaction used a triple FLAG 
tag on ASK1 (53).  I used a single FLAG epitope as part of my tandem tag on ASK1, so 
it is possible that the interaction between ASK1 and ATAD3A is mediated by the FLAG 
sequence.  By utilizing the endogenously expressing cell line, I was able to identify this 
interaction as a likely artifact. 
 Through quantitative MS analyses of ASK-TAG protein overexpression and 
native ASK protein expression in non-transfected cells, I was able to confirm the 
essential elements of the ASK signalosome hypothesis (2) and further extend our 
understanding of this system.  Through my SEC experiments, I confirmed previous 
observations of the distribution of the ASK1 protein across multiple high molecular 
weight complexes (3).  In contrast to a report that H2O2 led to the formation of a higher 
molecular weight ASK signalosome complex (3), I did not observe the same shift with a 
similar degree of MAPK activation by HNE.  I also detected most previously reported 
ASK1-interacting proteins at a significant enrichment over negative control IPs, thus 
confirming their associations with ASK1.  Several of these proteins exhibited dynamic 
associations with the overexpressed ASK1 upon HNE treatment, which is consistent 
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with previous observations of dynamic protein-protein associations with ASK1 in 
response to stress activation. 
 While I did observe several dynamic protein-protein interactions with ASK1, most 
of these proteins associated with ASK1 in a low stoichiometric ratio.  The SID-PRM 
assay targeted 26 of the previously reported ASK1-interacting proteins and quantified 7 
of them in ASK1 IPs from non-transfected cells.  Of these 7 proteins, ASK2 was present 
at a nearly 1:1 ratio with ASK1 and several 14-3-3 family proteins were collectively 
present at an approximately 0.5:1 ratio with ASK1.  The remaining proteins were 
observed at a 0.1:1 or lower ratio with ASK1.  Thus, my data points toward a core ASK1 
complex that consists of ASK1, ASK2, and 14-3-3 family members that associates with 
other proteins to execute MAPK pathway signaling. 
Interestingly, the expected size of a stoichiometric core ASK1 complex as I have 
described it here would be approximately 625 kDa (2 ASK1, 2 ASK2, and 1 14-3-3 
family protein), which corresponds well with the smallest commonly observed ASK1 
complex mass (approximately 669 kDa) in both my SEC experiments (Fig. A11B & C) 
and similar SEC analyses reported by Noguchi et. al. (21).  This suggests a core ASK1 
complex that may transiently associate with other proteins in a context-dependent 
fashion.  Indeed, the MW range for ASK1 complexes in the SEC analyses extends from 
approximately 669 kDa to as much as 3000 kDa (21), which could indicate the 
simultaneous co-existence of many different ASK1 signalosome complexes. 
 The presence of multiple 14-3-3 family members in the ASK1 core complex 
suggests that they may serve a key role as adapter proteins for bringing the ASK 
complex into contact with many other identified ASK interacting proteins.  Indeed, 
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finding equal stoichiometry between ASK1 and ASK2 in the signalosome complex 
raises the possibility that previously reported ASK1-interacting proteins may interact 
with both ASK proteins. Regardless of ASK protein binding specificity, the diversity of 
ASK-interacting protein partners likely enables the ASK signaling pathway to respond to 
a wide variety of environmental stressors.  ASK1 has been reported to interact with 
several other proteins to influence different signaling pathways (63-66) and recent 
studies explored the role of ASK1 in antiviral response and innate immunity (67-69).  
The core ASK complex thus may play a broader cellular role beyond activation of the 
MAPK pathway.  The large number of identified interacting proteins certainly points 
toward multifunctional roles of the core ASK complex in the cell.  Future investigations 
of the ASK1 core complex associations through targeted MS in different physiological 
contexts will be essential to test these hypotheses. 
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CHAPTER III 
 
DYNAMIC PHOSPHORYLATION OF APOPTOSIS SIGNAL REGULATING KINASE 1 
(ASK1) IN RESPONSE TO OXIDATIVE AND ELECTROPHILIC STRESS 
 
Introduction 
 
Apoptosis signal-regulating kinase 1 (ASK1) is a mitogen-activated protein 
kinase kinase kinase that acts as a critical sensor for cell stress.  Activation of ASK1 
results in downstream activation of p38 and JNK and subsequent stress response and 
apoptosis (1, 2).  ASK1 is known to be activated by a number of stress signals (3-18) 
and has been most notably studied for its role in transducing cellular responses to 
oxidative stress (3-5, 19).  Because ASK1 can be activated by such a broad range of 
signals, its activity must be carefully regulated by the cell.  One such means of 
regulation is the dynamic assembly of a multiprotein complex around ASK1 to control its 
function (see chapters 1 and 2). 
A second important method of ASK1 regulation is through differential 
phosphorylation.  Five phosphorylated residues have been reported as important for 
ASK1 regulation (Ser-83, Tyr-718, Thr-838, Ser-966, and Ser-1033), and another 24 
phosphorylations are listed on PhosphoSitePlus out of a total of 231 potential 
phosphorylation sites in the full-length protein (19-29).  The additional 24 sites were 
identified by global MS profiling studies and have not been examined for dynamic 
changes in response to activation of ASK1.  The five known dynamic sites (four 
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inactivating and one activating – Thr-838) have all been studied in the context of 
oxidative stress through treatment of cells with either TNF or H2O2.  What is not known 
is whether these five sites (and potentially others) serve as master phospho-regulators 
of ASK1 function for all stress signals or if dynamic phosphorylation at these sites is 
specific for oxidative stress only.  Indeed, the broader question of whether chemically 
distinct activators of ASK1 signaling produce distinct sets of dynamic phosphorylations 
has never been addressed. 
In order to test the generalizability of the phosphoregulation of ASK1, I chose to 
map phosphorylation sites in response to treatment of cells with either H2O2 or 4-
hydroxy-2-nonenal (HNE).  HNE is a prototypical electrophile that is generated 
endogenously under conditions of oxidative stress, but which acts through covalent 
adduction of protein cysteine thiol residues, as opposed to the reversible oxidation of 
protein thiols by H2O2 (30-33).  HNE has been previously shown to activate ASK1 and 
the downstream pathway to a similar degree as H2O2 (8) but whether or not ASK1 
senses these two chemicals by the same method is unknown.   
Because of the mechanistic difference between the reversible modification of 
ASK1 by H2O2 and the irreversible modification of ASK1 by HNE, I hypothesized that 
unique dynamic phosphorylation sites of ASK1 would be observed for each stressor, 
ultimately culminating in activation of the same stress pathway.  To test this hypothesis, 
I used both data-dependent shotgun liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) and parallel reaction monitoring (PRM) methods to map sites of 
phosphorylation and HNE adduction on ASK1 in response to treatment of an ASK1-
expressing cell line with H2O2 and HNE.  I report here the interplay between oxidative 
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and electrophilic activation of ASK1 and the phosphorylative response of the protein to 
these stressors.  This work was performed in collaboration with Carlos Morales 
Betanzos, Ph.D., a postdoctoral fellow in the Liebler laboratory. 
 
Experimental Procedures 
 
DNA construct 
The tandem-tagged construct for ASK1 (ASK1-TAG) was generated in a 
pcDNA3.1 plasmid (Life Technology, Grand Island, NY) by Genscript (Piscataway, NJ).  
The ASK1 sequence previously described (1) was modified to exchange the HA tag to a 
tandem HA-FLAG tag and is available from Addgene (#69726).   
 
Antibodies 
All ASK1 protein IPs were performed with EZview red anti-FLAG beads (Sigma-
Aldrich, St. Louis, MO).  Western blots were performed with the following primary 
antibodies: FLAG (8146S), phosphoP38 (9211S), P38 (9212S), phosphoJNK (4668S), 
JNK (9252S), ASK1 phosphoSer-83 (3761S), ASK1 phosphoSer-966 (3764S), and 
ASK1 phosphoThr-838 (3765S) from Cell Signaling Technology (Danvers, MA), and 
ASK1 (SC-5294; Santa Cruz Biotechnology, Dallas, TX).  Secondary antibodies were 
from Life Technology: anti-mouse 680 (A21058) and anti-rabbit 680 (A21109). 
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Cell lines and cell culture 
HEK-293 cells (CRL-1573; ATCC) were grown in DMEM (12430; Life 
Technology) supplemented with 10% fetal bovine serum (Atlas Biologicals, Fort Collins, 
CO) at 37°C in a humidified atmosphere with 5% CO2.  The ASK1-expressing cell line 
was generated from HEK-293 cells by transfecting the ASK1-TAG plasmid into cells 
using Lipofectamine 2000 (Life Technology) following the manufacturer’s instructions.  
Twenty-four hr following transfection, cells were split 1:10 and, after an additional 24 hr, 
were switched into selection medium consisting of the HEK-293 medium described 
above supplemented with 1.5 mg/mL Geneticin (Life Technology) and maintained in this 
medium for two weeks to select for cells expressing the plasmid of interest.  Stock cell 
cultures were maintained thereafter in HEK-293 media supplemented with 1 mg/mL 
Geneticin.  Prior to harvesting, cells were plated in 15 cm dishes in HEK-293 media 
supplemented with 0.5 mg/mL Geneticin.   
For the phosphorylation site studies, all cells were treated with 20 M MG-132 
(M8699; Sigma-Aldrich) in serum-free media for 2 hr at 37 °C prior to treatment with 
stressors.  Following proteasomal inhibition, cells were treated with ethanol (vehicle 
control-HNE, 0.08% v/v), 10 M HNE, 50 M HNE, PBS (vehicle control H2O2), 500 M 
H2O2, or 5,000 M H2O2.  The treatments were prepared in serum-free media and 
placed on the cells for 1 hr at 37°C.  Cells were then harvested with a cell scraper in the 
treatment medium and immediately centrifuged at 100 x g for 5 min at 4 °C.  The cell 
pellets then were washed twice with ice cold PBS and stored at -80 °C until use. 
For the HNE adduct site-mapping studies, HEK-293 cells transiently expressing 
ASK1-TAG were generated by transfection with Lipofectamine according to the 
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manufacturer’s instructions.  These cells were then treated with 20 M MG-132 for 2 hr 
at 37 °C prior to treatment with 50 M HNE for 1 hr at 37 °C.  These cells were then 
harvested and pelleted as described above. 
 
Cell viability assays 
 Cells were plated in a 96-well plate at a density of 10,000 cells/well and allowed 
to grow for 24 hr.  Medium was then removed and replaced with 100 L/well of serum-
free DMEM containing the appropriate concentration of HNE or H2O2 and the cells were 
incubated at 37°C for 24 hr.  To measure cell viability, 10 L/well of WST reagent 
(Sigma, 11644807001) was added and the cells were incubated for 1 hr.  Absorbance 
readings then were taken at 450 nm and 650 nm with a Spectramax M4 
spectrophotometer (Molecular Devices, Sunnyvale, CA) according to the manufacturer’s 
protocol. 
 
Immunoprecipitation and western blotting 
Frozen cell pellets were lysed on ice in 500 L of NETN buffer (50 mM HEPES 
pH 7.5, 150 mM NaCl, and 1% Igepal supplemented with 10 L/mL of HALT [78444; 
Life Technology] protease and phosphatase inhibitor), per 15 cm plate for 30 min with 
occasional inversion.  Lysates then were clarified by centrifugation at 10,000 × g for 10 
min at 4 °C.  Protein in the clarified lysates was measured with the BCA assay (Life 
Technology).  Protein concentrations then were adjusted to 2 mg/mL.  HNE-treated 
samples that were used for adduction site-mapping studies were further reduced with 2 
mM sodium borohydride (Sigma Aldrich) for 2 hr at room temperature with occasional 
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inversion; all other samples were not reduced.  Next, 5 mg of total protein was added in 
a final volume of 2.5 mL to antibody beads pre-washed with NETN.  For each IP, a 50 
L slurry of antibody-bead conjugate was washed twice with 1 mL of NETN prior to 
incubation with protein lysates.  After addition of the protein lysate, the beads were 
rotated at 4 °C for 1 hr to allow for capture of the target protein.  Following incubation, 
the beads were pelleted by centrifugation at 100 × g and the supernatant was 
discarded.  The beads were then washed twice with 1 mL of NETN buffer and the 
bound protein was resuspended in 80 L of lithium dodecyl sulfate (LDS) sample buffer 
diluted 1:1 with NETN and supplemented with 50 mM dithiothreitol (DTT).  The samples 
were then frozen at -80 °C until use.   
For western blot analysis, cell lysis and IP were carried out as described above.  
Gels were loaded with either 20 g of input protein or 2 L of IP and run for 50 min at a 
constant 180 V.  Proteins then were electrophoretically transferred to PVDF membranes 
(Life Technology) using the BioRad (Hercules, California) wet transfer system operated 
at a constant 300 mA current for 90 min at 4 °C.  Membranes were blocked in a 1:1 
mixture of Tris-buffered saline plus 0.05% Tween-20 (TBST) and blocking buffer (MB-
070; Rockland, Limerick, PA) for 1 hr at room temperature while rocking.  Primary 
antibodies were diluted (1:2000 for tag antibodies, 1:1000 for protein antibodies, and 
1:750 for phospho antibodies) in the same buffer used for blocking, added to the 
membrane, and incubated at 4 °C overnight with rocking.  After incubation, the 
membranes were washed three times with TBST, incubated with the appropriate 
secondary antibody diluted 1:10,000 in the same buffer used for the primary antibody, 
and allowed to rock for 30 min at room temperature.  The membranes were then 
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washed three times with TBST, visualized using a LiCor Odyssey (Lincoln, Nebraska), 
and analyzed using the Image Studio Lite software (LiCor). 
 
Preparation of peptides for MS analyses 
Bead-bound ASK1 protein was eluted in LDS buffer and heated at 95 °C for 10 
min prior to being loaded on a 10% Bis-Tris gel (NP0301; Life Technology).  The gels 
were loaded with 35 L of each sample elution and then were run at a constant 180 V 
for 3 min, after which the run was paused.  Each sample lane was then re-loaded with 
the remaining 35 L of each sample and the gel runs were resumed for an additional 47 
min.  Gels were then stained with Simply Blue safe stain (Life Technology) for 1 min in a 
microwave oven at maximum power and then allowed to destain in distilled water for 2-3 
hr.  For each sample, a single band from 100-200 kDa was cut and diced into ~1 mm 
cubes.  The gel pieces were placed into individual Eppendorf tubes and washed twice 
with 200 L of 100 mM ammonium bicarbonate (AmBic).  Samples were then reduced 
with 5 mM DTT in AmBic for 30 min at 60 °C while shaking at 1000 rpm and then 
alkylated with 10 mM iodoacetamide in AmBic for 20 min in the dark at room 
temperature.  Excess blue dye was then removed with three 200 L washes in 50 mM 
AmBic:acetonitrile (1:1, v/v) and the gel pieces were dehydrated in 100% acetonitrile.  
The gel pieces were rehydrated in 200 L of 25 mM AmBic with 200 ng of trypsin gold 
(Promega, Madison, WI) per sample and placed in a 37 °C incubator for 16 hr.  
Peptides were extracted from the SDS gel with three 20 min incubations in 200 L of 
60% acetonitrile / 40% water containing 1% formic acid and evaporated to dryness in 
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vacuo.  The peptides were resuspended in 30% acetonitrile / 70% water containing 
0.1% formic acid and stored at -80 °C until use.   
 
Mass spectrometry 
 Shotgun analyses of the single gel fraction samples were carried out on a Q 
Exactive Plus mass spectrometer (ThermoFisher Scientific, San Jose, CA) equipped 
with a Proxeon nLC1000 LC (ThermoFisher Scientific) and a Nanoflex source 
(ThermoFisher Scientific).  Peptide mixtures were evaporated in vacuo and 
resuspended in 2% acetonitrile / 98% water containing 0.1% formic acid and loaded 
onto an 20 cm long column with a 75 m internal diameter (PF360-75-10-N-5; New 
Objective, Woburn, MA) packed with 3 m particle size and 120 Å pore size ReproSil-
Pur C18-AQ resin (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) and separated 
over a 180 min gradient with a mobile phase containing aqueous acetonitrile and 0.1% 
formic acid programmed from 2-5% acetonitrile over 5 min, then 5 to 25% acetonitrile 
over 150 min, then 25-90% acetonitrile over 5 min, followed by 20 min at 90% 
acetonitrile, all at a flow rate of 300 nL/min.  A single MS1 scan from m/z 300-1800 at 
70,000 resolution with an automatic gain control (AGC) value of 3e6 and max injection 
time of 64 msec was recorded as profile data.  A top 10 method was used, whereby the 
10 most intense precursors were automatically chosen for MS2 analysis and a dynamic 
exclusion window of 20 sec was employed.  For each MS2 scan, a resolution of 17,500, 
an AGC value of 1e5, a max injection time of 175 msec, a 1.4 m/z isolation window, and 
a normalized collision energy of 27 were used and centroid data were recorded. 
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 PRM assays were performed on the same Q Exactive Plus instrument and LC 
system using the same gradient described above.  The PRM method consisted of an 
MS1 scan at 17,500 resolution with an AGC value of 3e6, max injection time of 30 
msec, and scan range from m/z 380-1500 recorded as profile data.  This was followed 
by 10 targeted MS2 scans at a resolution of 17,500 and with an AGC value of 1e5, a 
max injection time of 175 msec, a 0.5 m/z isolation window, a fixed first mass of 150 
m/z, normalized collision energy of 27, and recorded as profile data.  The targeted-MS2 
methods were controlled with a timed inclusion list containing the target precursor m/z 
value, charge, and a 10 min retention time window that was determined from shotgun 
analyses. 
 
Data analysis 
 Shotgun runs were converted to mzml format using Proteowizard version 
3.0.5211 (34).  The mzml files were searched using MS-GF+ version 9517 (35).  A 
semi-tryptic search was employed with a maximum of four missed cleavages allowed.  
A fixed carbimidomethyl modification on cysteine, a variable oxidation on methionine, 
and a pyro-glu on glutamine were allowed with a maximum of 3 dynamic modifications 
per peptide with a precursor ion tolerance of 10 ppm and a fragment ion tolerance of 20 
ppm.  For phosphorylation studies, an additional variable modification of 79.966331 Da 
on serine, threonine, or tyrosine was employed.  For the HNE adduction studies, the 
carbimidomethylation modification on cysteine was changed to a variable search 
parameter and a variable mass of 158.130680 Da for reduced HNE adducts on cysteine 
was used.  A target-decoy search was employed using a reverse sequence database to 
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allow calculation of FDR for peptide-spectrum matches (36).  Protein-level FDR was 
calculated by dividing the number of reverse sequence proteins identified by the total 
number of proteins identified, multiplying by 2 and converting to a percent.  All search 
result files were parsimoniously assembled in IDPicker 3 version 3.1.8754.0 (37).  
 PRM runs were designed and analyzed using Skyline (38) and 3 transitions per 
peptide were used for quantitation.  To normalize the data between independent runs, 
the integrated peak area for each peptide was divided by the total quantifiable signal 
observed in each run.  This normalization corrected for both instrumental variance and 
slight sample to sample discrepancies that occurred during immunoprecipitation. 
All phosphorylation site assignments were confirmed by manual spectrum 
annotation as previously described (39).  In summary, for each peptide, precursor purity 
was confirmed by MS1, major peaks were unambiguously assigned, and direct 
evidence of site modifications was required.  The precursor purity was confirmed by 
examining the MS1 scan immediately prior to peptide isolation to determine if any mass 
aside from the targeted peptide fell within the isolation window employed for the run (1.4 
m/z for shotgun or 0.5 m/z for PRM).  If any other mass was present at more than 10% 
of the intensity of the targeted precursor, this spectrum was not considered for further 
evaluation.  Additionally, the selected peptide peak was required to have no more than 
10 ppm mass error in the MS1 scan.  Spectra that passed this filter were then manually 
annotated using mMass version 5.5.0 (40, 41), which allowed for automated spectral 
annotations of b- and y-ions, internal fragment ions, neutral loss ions for H2O, NH3, CO, 
and H3PO4, as well as annotations of phospho-specific mass-shifted ions.  Assigned 
peaks were required to explain at least half of the total ion current for each spectrum to 
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be considered acceptable.  Furthermore, for peptides with phosphorylated threonine or 
serine residues, the presence of a phosphoric acid neutral loss peak (from either the 
precursor or a fragment ion) was required for the spectrum to be accepted.  Peptides 
that passed all of these filters were then divided into two categories: peptides with or 
without ambiguous site localizations.  Peptides with ambiguous PTM site localizations 
were those where more than one modifiable residue was present in the sequence such 
that the PTM could not be definitively assigned to one residue (e.g. a peptide with two 
side-by-side serines).  Unambiguous PTM assignments were those spectra where no 
other site-assignment of the PTM could reasonably explain the MS/MS data. 
 
Experimental Design and Statistical Rationale  
 Treatment of ASK1-TAG cells by HNE and H2O2 were each performed in 
biological quadruplicate (i.e., in four separate cultures of cells).  PRM analyses of 
phosphorylated peptides in HNE-treated cells were performed in triplicate; all other MS 
assays for phosphopeptide detection and quantitation were performed in quadruplicate.  
The HNE adduct site-mapping experiments were performed in biological triplicate.  
Statistical comparisons of the relative amount of each phosphorylated peptide were 
performed using the Student’s t-test as pair-wise comparisons of each treatment 
concentration to the zero level treatment.  Replicate numbers were chosen to be 
sufficient to evaluate reproducibility and provide enough data points for the t-test. 
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Results 
 
Establishment of experimental system 
 In order to investigate the differential stress-sensing ability of ASK1, I first stably 
expressed a tandem-tagged version of the ASK1 protein (ASK1-TAG) in HEK-293 cells.  
I then characterized the response of these cells to HNE and H2O2 treatment using WST 
cell survivability assays and Western blot-based MAPK pathway activation assays.  In 
the 24 hr WST assay, the treated cells were found to have an EC50 concentration of 
approximately 10 M for HNE and 36 M for H2O2 (Fig III-1 A & B).  Despite the low 
EC50 value obtained for the H2O2 cells, use of this concentration in a one hr exposure 
produced minimal stress activation of the ASK1 MAPK pathway (data not shown).  
Thus, I conducted a dose-escalation experiment at higher concentrations of H2O2 to find 
a treatment level at which the downstream pathway was activated similarly to treatment 
with HNE at 10 M and 50 M (Fig. III-1C).  Based on the results of the pathway 
activation Western analyses, I chose to use 0, 10, and 50 M HNE and 0, 500, and 
5,000 M H2O2 for all further studies. 
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Figure III-1. ASK1-TAG cell characterization.  Twenty-four hr WST-based cell death 
assays were performed with (A) HNE and (B) H
2
O
2
 to determine the EC
50
 
concentration for each compound in the cell line.  (C) Western blot showing activation 
of the ASK1 MAPK pathway after 1 hr with each compound at varying concentrations. 
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Purification of phosphorylated ASK1 peptides  
In order to identify phosphorylated ASK1 peptides, the ASK1 cells were first 
blocked with MG-132 to inhibit proteasomal degradation and then treated with either 
HNE or H2O2 at the concentrations described above.  Following treatment, cells were 
harvested and lysed, and the tagged ASK1 protein was immunopurified with anti-FLAG 
beads.  The purified ASK1 was separated by one-dimensional gel electrophoresis and 
analyzed by MS as shown in figure III-2.   
I chose to employ a biphasic approach to identifying phosphorylated ASK1 
peptides by first performing a data-dependent shotgun analysis on the immunopurified 
samples in order to identify as many potential sites of phosphorylation as possible 
(phase 1).  I next targeted all of these sites by reanalyzing the same samples with a 
scheduled PRM method to quantify each peptide (phase 2).  I then performed manual 
annotation of the putative phosphopeptide spectra obtained in the PRM analysis to 
confirm which sites were truly phosphorylated.  Integrated peak areas for this final list of 
validated sites were used for concentration-dependent quantitation of each 
phosphopeptide at each concentration level compared to the control (0 M) level.  Table 
III-1 lists all of the phosphopeptides in each treatment condition that were found in the 
shotgun and PRM analyses and passed manual validation criteria.  
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Figure III-2.  Workflow for identification, validation, and quantitation of 
phosphorylated peptides on ASK1. 
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Table III-1.  Manually validated phosphorylation sites identified by MS 
in ASK1 under two different stress stimuli. 
Status1 A.A. site2 Stimulation Identified sequences 
Known 
Known 
Known 
Known 
S82/83 
S82/83 
S82/83 
S82/83 
Both  
Both 
Both 
H2O2 
GSSVGGGSRR 
GRGSSVGGGSR 
GRGSSVGGGSRR 
GSSVGGGSR 
Novel T140/141 HNE LDFGETTVLDR 
Novel S268/269 H2O2 VAQASSSQYFR 
Novel Y355 H2O2 FHYAFALNR 
Known 
Known 
T947/S952 
T947/S952 
HNE 
Both 
KKKTQPKLSALSAGSNEYLR 
KKTQPKLSALSAGSNEYLR 
Novel S955 Both  LSALSAGSNEYLR 
Known S958 Both LSALSAGSNEYLR 
 
 
S955/S958 
S955/S958 
HNE 
HNE 
TQPKLSALSAGSNEYLR 
KTQPKLSALSAGSNEYLR 
Novel 
Novel 
T1000/S1004 
T1000/S1004 
HNE 
HNE 
TRAKSCGERDVKGIR 
TRAKSCGERDVK 
Novel S1004 Both  AKSCGERDVK 
Known T1059 H2O2 ILTEDQDKIVR 
Novel S1240 HNE SLNVQLGR 
1Known=previously reported site, Novel=unreported phosphorylation site 
2In some cases, site assignment may remain ambiguous even after manual 
validation.  Here, site assignment is presented for the residues with the most 
supporting evidence. 
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For the HNE-treated samples, an initial list of 25 putative phosphosites from the 
shotgun data was reduced to 13 manually validated sites.  In the H2O2-treated samples, 
an initial 23 putative phosphorylation sites were reduced to 12 manually validated sites.  
For many of these peptides, the exact site of phosphorylation could not be localized by 
the MS/MS evidence.  However, in all cases, I was able to narrow the potential list of 
sites down to a maximum of two residues, which were often adjacent, but was unable to 
distinguish between them due to a lack of definitive evidence for one site over the other.  
In total, there were 10 unique sites identified between both treatments and four of these 
were present in both HNE and H2O2 treated samples.  Of these 10 sites, six have not 
previously been reported.  Annotated MS/MS spectra for each of these sites are 
provided in Fig. B-1. 
Of the five known dynamic phosphorylation sites, only one (Ser-83) was detected 
in my MS experiments.   For the other four sites, Tyr-718 and Ser-1033 were originally 
identified in different stress and cellular contexts than were employed here and have not 
been observed in response to H2O2 stress.  Ser-966 was been observed to be dynamic 
in response to oxidative stress before but was not observed here, possibly due to the 
fact that the tryptic peptide would have been fairly long (28 amino acids) and may not 
have ionized well.  Even if it had been detected, it would have contained 8 serine 
residues, which would have made site localization impossible.  Thr-838 is the sole 
known activating site on ASK1 and is expected to be observed as dynamic in response 
to both stressors used here.  However the peptide containing this site was not detected 
in the PRM runs, is also somewhat long (24 amino acids), and contains four threonine 
residues.  In an effort to obtain information on this site, I purchased a synthetic standard 
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for the phosphorylated peptide but was unable to reliably detect it except at very high 
concentrations (data not shown) which indicates that this peptide may be poorly ionized. 
 
Validation of MS methodology and comparison to antibody-based methods 
 In order to validate the MS methodology, I compared Western blot-based results 
for a well-characterized phosphorylation in ASK1 (Ser-83) to the PRM results (Fig. III-3).  
In response to treatment with HNE, both the Western blot and the PRM results show a 
decrease in the amount of phosphorylation at Ser-83.  Because the peptide that 
contains Ser-83 also contains a serine at position 82, I was not able to differentiate 
between the two potential phosphorylation sites with the MS/MS data.  However, in this 
case the assignment to Ser-83 is supported also by previous literature evidence, which 
includes mutational analyses (22, 42). 
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Figure III-3.  Comparison of Western blot and PRM for pS83 detection.  
(A) Western blot of ASK1-pS83 and the FLAG tag in ASK1-TAG cells with or 
without HNE treatment.  (B) Quantitation of the pS83 containing peptide in 
PRM assays at both concentration points. 
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Dynamics of phosphorylation sites in HNE- and H2O2- treated samples 
 In ASK1-TAG cells treated with three concentrations of HNE, 13 
phosphopeptides covering six different phosphorylation sites were quantified (Fig. B-2).  
Of the six phosphosites, five exhibited a significant dynamic response to HNE treatment 
in at least one of the two treatment levels compared to the zero treatment samples (Fig. 
III-4A). 
 After treatment of the cells with H2O2, 12 phosphopeptides covering nine different 
phosphorylation sites were quantified (Fig. B-3).  Of these nine phosphosites, seven 
displayed significant concentration-based dynamic responses to at least one of the 
treatment levels compared to the zero treatment level (Fig. III-4B).   
 In some cases, peptides exhibited consistent trends across both concentration 
levels for one of the stressors, but failed to show a significant difference in one of the 
comparisons due to a high variance in the measurements for that treatment level.  For 
example, in Fig. III-4A, the peptide for S82|S83 shows significance for only the 50 M v 
0 M comparison, even though the average fold change is very similar for the 10 M v 0 
M comparison.  As can be seen from Fig. B-2A (2), there is one high measured value 
in the 10 M treatment that eliminates the ability to statistically characterize this peptide 
at this concentration. 
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Figure III-4.  Phosphopeptides significantly different at each concentration point.  ASK1-
TAG cells were treated with (A) HNE and (B) H2O2 at two different concentrations for each 
molecule.  Average peak areas for each peptide were normalized to the 0 M treatment level 
and a fold change was calculated.  Peptides with significant differences from the zero point were 
denoted with asterisks.  Each site is denoted by a superscript, which maps to supporting 
supplemental data figures.  See figures B-2 for (A) and B-3 for (B). 
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Antibody-based investigation of phosphorylation dynamics 
 Of the previously reported dynamic phosphorylation sites, I only was able to 
observe Ser-83 with the MS method.  Many of the other phosphorylation sites were on 
peptides that were not amenable to tryptic digestion.  In order to track the activation 
status of ASK1, I performed Western blots with the Thr-838 ASK1 phospho-antibody 
(Fig. III-5).  Phosphorylation of Thr-838 increased with increasing treatment of H2O2, but 
only exhibited a modest increase with HNE-treatment.  This is in contrast to data from 
the previous chapter (see Figs. A-2 & A-6B) where concentration- and time-dependent 
increasing phosphorylation of Thr-838 was observed in response to HNE treatment.  
The HNE-treated lysates used here had been stored at -80 oC for several months and it 
is possible that this phosphosite is labile in lysate over time.   
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Figure III-5.  Western blot data for ASK1 activation.  Phosphorylation of Thr-838 on 
ASK1 was increased with increasing concentration of (A) HNE and (B) H
2
O
2
 after a 1 hr 
treatment. 
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Identification of HNE adduction sites in HNE-treated samples 
 HEK-293 cells transiently expressing ASK1-TAG were treated with MG-132 
followed by 50 M HNE treatment.  Cys-928 and Cys-1005 were identified as two 
unique adduct sites in this experiment (Fig. B-4).  Interestingly, both sites were near the 
C-terminus of ASK1 and the Cys-1005 site is located immediately adjacent to Ser-1004, 
while the Cys-928 site is located in the kinase domain. 
 
Comparison of phosphosites across treatments 
 Between both the HNE- and the H2O2-treated cells with MS and Western blot 
methodologies, I identified a total of 11 phosphosites, with five of those shared between 
the two treatments.  Figure III-6 diagrams the nine dynamic phosphosites identified by 
MS and summarizes how each site changes in response to each treatment as well as 
lists the sites of HNE adduction.  Of these nine dynamic sites, five were not previously 
reported. 
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Figure III-6.  Summary of significantly dynamic phosphosites on ASK1.  Each 
large square represents a single phosphosite detected on ASK1.  The top two interior 
squares are the two doses of H2O2 used (low to high -> left to right) and the bottom two 
interior squares are for HNE.  A red square indicates that the phosphosite significantly 
increased in phosphorylation at the corresponding treatment level over the zero level 
and a green square indicates that the site significantly decreased.  White squares 
indicate either no change or non-detection.  Black squares indicate HNE adduction 
sites. 
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Discussion 
 
 ASK1 contains 231 serine, threonine, and tyrosine residues that could be 
phosphorylated and has been shown to be regulated by phosphorylations on at least 
five of these.  Four sites (Ser-83, Tyr-718, Ser-966, and Ser-1033) have been reported 
to negatively regulate the function of ASK1, whereas one site (Thr-838) has been 
reported to enhance it.  All five previously reported dynamic sites were only studied via 
perturbation with H2O2 and TNF.  However, ASK1 is responsive to more stress signals 
than just these, including the lipid electrophile HNE.  It is unknown whether ASK1 
senses all activating stressors by the same mechanism.  I therefore asked how 
phosphorylation of ASK1 changes in response to HNE stress as compared to H2O2 
stress in order to see if there were different sensing mechanisms for these two 
molecules.  I first performed shotgun MS in cells treated with differing concentrations of 
HNE and H2O2 to identify potential sites of phosphorylation on ASK1 in response to both 
stressors and created a target list of putative phosphopeptides.  I then utilized targeted 
PRM assays to track the dynamics of these putative sites in the same samples.  I 
identified and quantified a total of 10 phosphosites on 18 different peptide forms and 
monitored one additional phosphosite via Western blot across both treatment groups.  
Of these 11 sites, 10 exhibited a dynamic response to at least one treatment condition 
and five were dynamic in both HNE- and H2O2-treated cells. 
 Most previous studies of ASK1 phosphorylation have utilized mutagenesis and 
Western blot methods to identify important modification sites.  All of the studies 
describing the five previously known dynamic sites have been done in this way.  
However, this is a slow and laborious process that requires a priori knowledge of which 
155 
 
residues to mutate.  With so many potential sites of phosphorylation in ASK1, an 
unbiased approach to phosphosite identification is needed.  Shotgun proteomic assays 
have been used extensively in recent years to identify phosphorylation sites on 
thousands of proteins.  Although MS assays have greatly expedited the identification of 
phosphosites, obtaining dynamic information about those sites still typically relies on 
mutagenesis or phospho-specific antibody generation.  The approach in this study was 
to utilize targeted proteomics to track the dynamics of phosphorylation on all detected 
phosphosites in ASK1 in response to two different treatments.  With this approach, I 
rapidly pinpointed which sites were more responsive in each treatment condition.  This 
generated a smaller list of interesting sites that could be examined in future studies. 
 Of the nine phosphosites listed in Figure III-6, four were found to be dynamic in 
both H2O2- and HNE-treated cells, along with Thr-838 as shown in the Western blot in 
Figure III-5.  One of these sites (pSer-83) is well known as a dynamically-modified site 
in ASK1.  Previous reports described a decrease in phosphorylation upon treatment 
with oxidants and subsequent activation of ASK1.  My HNE data was in line with this 
observation and suggests that this site may act as a general activity readout for ASK1.  
However, in the H2O2-treated samples, I observed an increase in the amount of pSer-83 
upon treatment with 5000 M H2O2.  This is counter to what has been previously 
reported; although previous reports typically only examined phosphorylation of this 
residue after H2O2 treatments of 500 M or less (23, 43) and once at 2 mM (24).  It is 
therefore possible that this residue is dephosphorylated at lower oxidant concentrations 
and then increasingly phosphorylated at higher oxidant levels.  While not significant, my 
data do show a downward trend in the phosphorylation level of Ser-83 at 500 M H2O2 
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treatment prior to the significant increase at the highest treatment level.  Importantly, 
AKT1 is the kinase known to phosphorylate ASK1 at Ser-83 and H2O2 has been shown 
to stimulate AKT1 activity in a time- and dose-dependent manner (44-46).  Thus, there 
may be a switch point at which the activity of AKT1 outcompetes the activity of the 
phosphatase that dephosphorylates Ser-83. 
 Of the other four sites that were found to be in common between the two stress 
types, three exhibited consistent dynamics between both HNE and H2O2.  The 
previously known dynamic site Thr-838 increased in phosphorylation here in response 
to treatment with H2O2 and in previous studies in response to treatment with HNE.  This 
observation is consistent with previous reports in the literature and confirms the validity 
of this site as a marker of ASK1 activity.  Additionally, Ser-955 and Ser-958 both 
exhibited an increase in phosphorylation upon treatment with either stressor, which 
suggests that these two sites may also be good markers for ASK1 activity. 
 The final phosphosite that was observed on ASK1 in both treatments was Ser-
1004.  In the H2O2-treated cells, Ser-1004 was increasingly phosphorylated at the 
higher concentration level.  However, in the HNE-treated cells, Ser-1004 
phosphorylation decreased with increasing HNE treatment.  Interestingly, one of the two 
identified HNE adduct sites was on Cys-1005.  It is possible that the decreased 
phosphorylation observed at this residue in HNE-treated samples was due to 
interference by the adjacent adducted cysteine residue, although the stoichiometries of 
HNE adduction and serine phosphorylation remain to be investigated.   
 HNE and H2O2 treatments also resulted in several novel changes.  The HNE-
treated cells had two phosphosites that were uniquely dynamic and the H2O2-treated 
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cells had three uniquely dynamic residues, as well as one unique non-dynamic residue.  
The presence of phosphosites that are specific to one stress type could serve as a 
cellular readout of what specific type of stress is being sensed by ASK1 and could 
indicate that ASK1 senses these two stressors in different ways. 
 Although ASK1 seems to sense HNE and H2O2 through different mechanisms, 
the end result of activation by either of these molecules is the same.  The presence of a 
core group of phosphorylated residues in ASK1 that exhibit similar dynamics between 
two dissimilar stress molecules could start to explain how a single sensor protein is able 
to transduce so many different chemical signals into a single pathway response.  It is 
possible that many or all of the stressors that activate ASK1 will exert fine control over 
the phosphorylation of Thr-838, Ser-955, and Ser-958 residues to control the activity of 
ASK1.  Future studies with additional stress activators of ASK1 will be necessary to test 
this hypothesis. 
  
158 
 
References 
 
1. Ichijo, H., Nishida, E., Irie, K., ten Dijke, P., Saitoh, M., Moriguchi, T., Takagi, M., 
Matsumoto, K., Miyazono, K., and Gotoh, Y. (1997) Induction of apoptosis by ASK1, a 
mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 
275, 90-94 
2. Shiizaki, S., Naguro, I., and Ichijo, H. (2013) Activation mechanisms of ASK1 in 
response to various stresses and its significance in intracellular signaling. Adv Biol 
Regul 53, 135-144 
3. Takeda, K., Noguchi, T., Naguro, I., and Ichijo, H. (2008) Apoptosis signal-
regulating kinase 1 in stress and immune response. Annu Rev Pharmacol Toxicol 48, 
199-225 
4. Saitoh, M., Nishitoh, H., Fujii, M., Takeda, K., Tobiume, K., Sawada, Y., 
Kawabata, M., Miyazono, K., and Ichijo, H. (1998) Mammalian thioredoxin is a direct 
inhibitor of apoptosis signal-regulating kinase (ASK) 1. The EMBO journal 17, 2596-
2606 
5. Matsuzawa, A., Saegusa, K., Noguchi, T., Sadamitsu, C., Nishitoh, H., Nagai, S., 
Koyasu, S., Matsumoto, K., Takeda, K., and Ichijo, H. (2005) ROS-dependent activation 
of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate 
immunity. Nat Immunol 6, 587-592 
6. Takeda, K., Matsuzawa, A., Nishitoh, H., Tobiume, K., Kishida, S., Ninomiya-
Tsuji, J., Matsumoto, K., and Ichijo, H. (2004) Involvement of ASK1 in Ca2+-induced 
p38 MAP kinase activation. EMBO reports 5, 161-166 
7. Nishitoh, H., Matsuzawa, A., Tobiume, K., Saegusa, K., Takeda, K., Inoue, K., 
Hori, S., Kakizuka, A., and Ichijo, H. (2002) ASK1 is essential for endoplasmic reticulum 
stress-induced neuronal cell death triggered by expanded polyglutamine repeats. 
Genes & development 16, 1345-1355 
8. Soh, Y., Jeong, K. S., Lee, I. J., Bae, M. A., Kim, Y. C., and Song, B. J. (2000) 
Selective activation of the c-Jun N-terminal protein kinase pathway during 4-
hydroxynonenal-induced apoptosis of PC12 cells. Mol Pharmacol 58, 535-541 
9. Lee, K. W., Zhao, X., Im, J. Y., Grosso, H., Jang, W. H., Chan, T. W., Sonsalla, 
P. K., German, D. C., Ichijo, H., Junn, E., and Mouradian, M. M. (2012) Apoptosis 
signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation. PLoS 
One 7, e29935 
10. Lim, P. L., Liu, J., Go, M. L., and Boelsterli, U. A. (2008) The mitochondrial 
superoxide/thioredoxin-2/Ask1 signaling pathway is critically involved in troglitazone-
induced cell injury to human hepatocytes. Toxicol Sci 101, 341-349 
159 
 
11. Usuki, F., Fujita, E., and Sasagawa, N. (2008) Methylmercury activates 
ASK1/JNK signaling pathways, leading to apoptosis due to both mitochondria- and 
endoplasmic reticulum (ER)-generated processes in myogenic cell lines. 
Neurotoxicology 29, 22-30 
12. Nakagawa, H., Maeda, S., Hikiba, Y., Ohmae, T., Shibata, W., Yanai, A., 
Sakamoto, K., Ogura, K., Noguchi, T., Karin, M., Ichijo, H., and Omata, M. (2008) 
Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver 
injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology 135, 1311-1321 
13. Shinkai, Y., Iwamoto, N., Miura, T., Ishii, T., Cho, A. K., and Kumagai, Y. (2012) 
Redox cycling of 1,2-naphthoquinone by thioredoxin1 through Cys32 and Cys35 causes 
inhibition of its catalytic activity and activation of ASK1/p38 signaling. Chem Res Toxicol 
25, 1222-1230 
14. Kuo, C. T., Chen, B. C., Yu, C. C., Weng, C. M., Hsu, M. J., Chen, C. C., Chen, 
M. C., Teng, C. M., Pan, S. L., Bien, M. Y., Shih, C. H., and Lin, C. H. (2009) Apoptosis 
signal-regulating kinase 1 mediates denbinobin-induced apoptosis in human lung 
adenocarcinoma cells. J Biomed Sci 16, 43 
15. Kwon, M. J., Jeong, K. S., Choi, E. J., and Lee, B. H. (2003) 2,3,7,8-
Tetrachlorodibenzo-p-dioxin (TCDD)-induced activation of mitogen-activated protein 
kinase signaling pathway in Jurkat T cells. Pharmacol Toxicol 93, 186-190 
16. Pramanik, K. C., and Srivastava, S. K. (2012) Apoptosis signal-regulating kinase 
1-thioredoxin complex dissociation by capsaicin causes pancreatic tumor growth 
suppression by inducing apoptosis. Antioxid Redox Signal 17, 1417-1432 
17. Ouyang, M., and Shen, X. (2006) Critical role of ASK1 in the 6-
hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. J 
Neurochem 97, 234-244 
18. Yang, W., Tiffany-Castiglioni, E., Koh, H. C., and Son, I. H. (2009) Paraquat 
activates the IRE1/ASK1/JNK cascade associated with apoptosis in human 
neuroblastoma SH-SY5Y cells. Toxicol Lett 191, 203-210 
19. Gotoh, Y., and Cooper, J. A. (1998) Reactive oxygen species- and dimerization-
induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-alpha 
signal transduction. J Biol Chem 273, 17477-17482 
20. He, Y., Zhang, W., Zhang, R., Zhang, H., and Min, W. (2006) SOCS1 inhibits 
tumor necrosis factor-induced activation of ASK1-JNK inflammatory signaling by 
mediating ASK1 degradation. J Biol Chem 281, 5559-5566 
21. Yu, L., Min, W., He, Y., Qin, L., Zhang, H., Bennett, A. M., and Chen, H. (2009) 
JAK2 and SHP2 reciprocally regulate tyrosine phosphorylation and stability of 
proapoptotic protein ASK1. J Biol Chem 284, 13481-13488 
160 
 
22. Kim, A. H., Khursigara, G., Sun, X., Franke, T. F., and Chao, M. V. (2001) Akt 
phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell 
Biol 21, 893-901 
23. Gu, J. J., Wang, Z., Reeves, R., and Magnuson, N. S. (2009) PIM1 
phosphorylates and negatively regulates ASK1-mediated apoptosis. Oncogene 28, 
4261-4271 
24. Seong, H. A., Jung, H., Ichijo, H., and Ha, H. (2010) Reciprocal negative 
regulation of PDK1 and ASK1 signaling by direct interaction and phosphorylation. J Biol 
Chem 285, 2397-2414 
25. Goldman, E. H., Chen, L., and Fu, H. (2004) Activation of apoptosis signal-
regulating kinase 1 by reactive oxygen species through dephosphorylation at serine 967 
and 14-3-3 dissociation. J Biol Chem 279, 10442-10449 
26. Min, W., Lin, Y., Tang, S., Yu, L., Zhang, H., Wan, T., Luhn, T., Fu, H., and Chen, 
H. (2008) AIP1 recruits phosphatase PP2A to ASK1 in tumor necrosis factor-induced 
ASK1-JNK activation. Circ Res 102, 840-848 
27. Fujii, K., Goldman, E. H., Park, H. R., Zhang, L., Chen, J., and Fu, H. (2004) 
Negative control of apoptosis signal-regulating kinase 1 through phosphorylation of Ser-
1034. Oncogene 23, 5099-5104 
28. Morita, K., Saitoh, M., Tobiume, K., Matsuura, H., Enomoto, S., Nishitoh, H., and 
Ichijo, H. (2001) Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5) 
in response to oxidative stress. EMBO J 20, 6028-6036 
29. Cho, Y. C., Park, J. E., Park, B. C., Kim, J. H., Jeong, D. G., Park, S. G., and 
Cho, S. (2015) Cell cycle-dependent Cdc25C phosphatase determines cell survival by 
regulating apoptosis signal-regulating kinase 1. Cell Death Differ 
30. Benedetti, A., Comporti, M., and Esterbauer, H. (1980) Identification of 4-
hydroxynonenal as a cytotoxic product originating from the peroxidation of liver 
microsomal lipids. Biochim Biophys Acta 620, 281-296 
31. Schopfer, F. J., Cipollina, C., and Freeman, B. A. (2011) Formation and signaling 
actions of electrophilic lipids. Chem Rev 111, 5997-6021 
32. Fritz, K. S., Kellersberger, K. A., Gomez, J. D., and Petersen, D. R. (2012) 4-
HNE adduct stability characterized by collision-induced dissociation and electron 
transfer dissociation mass spectrometry. Chem Res Toxicol 25, 965-970 
33. West, J. D., and Marnett, L. J. (2006) Endogenous reactive intermediates as 
modulators of cell signaling and cell death. Chem Res Toxicol 19, 173-194 
161 
 
34. Kessner, D., Chambers, M., Burke, R., Agus, D., and Mallick, P. (2008) 
ProteoWizard: open source software for rapid proteomics tools development. 
Bioinformatics 24, 2534-2536 
35. Kim, S., and Pevzner, P. A. (2014) MS-GF+ makes progress towards a universal 
database search tool for proteomics. Nature communications 5, 5277 
36. Elias, J. E., and Gygi, S. P. (2007) Target-decoy search strategy for increased 
confidence in large-scale protein identifications by mass spectrometry. Nat Methods 4, 
207-214 
37. Ma, Z. Q., Dasari, S., Chambers, M. C., Litton, M. D., Sobecki, S. M., 
Zimmerman, L. J., Halvey, P. J., Schilling, B., Drake, P. M., Gibson, B. W., and Tabb, D. 
L. (2009) IDPicker 2.0: Improved protein assembly with high discrimination peptide 
identification filtering. Journal of proteome research 8, 3872-3881 
38. MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M., Finney, G. L., 
Frewen, B., Kern, R., Tabb, D. L., Liebler, D. C., and MacCoss, M. J. (2010) Skyline: an 
open source document editor for creating and analyzing targeted proteomics 
experiments. Bioinformatics 26, 966-968 
39. Nichols, A. M., and White, F. M. (2009) Manual validation of peptide sequence 
and sites of tyrosine phosphorylation from MS/MS spectra. Methods Mol Biol 492, 143-
160 
40. Strohalm, M., Kavan, D., Novak, P., Volny, M., and Havlicek, V. (2010) mMass 3: 
a cross-platform software environment for precise analysis of mass spectrometric data. 
Anal Chem 82, 4648-4651 
41. Niedermeyer, T. H., and Strohalm, M. (2012) mMass as a software tool for the 
annotation of cyclic peptide tandem mass spectra. PLoS One 7, e44913 
42. Yuan, Z. Q., Feldman, R. I., Sussman, G. E., Coppola, D., Nicosia, S. V., and 
Cheng, J. Q. (2003) AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by 
phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem 278, 
23432-23440 
43. Zhang, R., Luo, D., Miao, R., Bai, L., Ge, Q., Sessa, W. C., and Min, W. (2005) 
Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 24, 
3954-3963 
44. Blanc, A., Pandey, N. R., and Srivastava, A. K. (2004) Distinct roles of Ca2+, 
calmodulin, and protein kinase C in H2O2-induced activation of ERK1/2, p38 MAPK, 
and protein kinase B signaling in vascular smooth muscle cells. Antioxid Redox Signal 
6, 353-366 
162 
 
45. Cui, X. L., Ding, Y., Alexander, L. D., Bao, C., Al-Khalili, O. K., Simonson, M., 
Eaton, D. C., and Douglas, J. G. (2006) Oxidative signaling in renal epithelium: Critical 
role of cytosolic phospholipase A2 and p38(SAPK). Free Radic Biol Med 41, 213-221 
46. Shaw, M., Cohen, P., and Alessi, D. R. (1998) The activation of protein kinase B 
by H2O2 or heat shock is mediated by phosphoinositide 3-kinase and not by mitogen-
activated protein kinase-activated protein kinase-2. Biochem J 336 ( Pt 1), 241-246 
 
 
163 
 
CHAPTER IV 
 
PERSPECTIVE 
 
Summary 
 
 There were two driving questions for this body of work.  The first was how ASK1 
is able to act as a sensor protein capable of detecting molecules of diverse chemotypes 
and integrate them into a single response pathway.  The second question was whether 
the hypothesized ASK1 signalosome exists and, if it does, what the exact membership 
of this multiprotein complex might be.  In answer to these questions, I hypothesized that 
ASK1 or its complex members are modified by electrophiles (represented by HNE), 
resulting in pathway activation and formation of a consensus post-activation 
signalosome, along with a change in the phosphorylation pattern on ASK1.  The studies 
presented in chapter II addressed the existence of the signalosome and proved that 
there is a multiprotein ASK1 complex present in the cell.  However, the large two-state 
signalosome concept as it has been presented in the literature is inconsistent with my 
data, which suggests the concurrent presence of many diverse signalosomes in the cell 
that all share a core set of proteins.  The work presented in chapter III begins to suggest 
how ASK1 is able to integrate such a diverse array of chemical signals.  I utilized PRM 
assays to demonstrate that two distinct chemical species were capable of activating 
ASK1 to a similar degree with both a core set of common phosphorylations and a 
unique phosphorylation signature for each stress. 
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ASK1 protein complex composition and dynamics 
 
Current practices and understanding in the ASK1 field 
In the field of multiprotein complex analysis in general, and for ASK1 in particular, 
the predominate method for both detection of protein-protein interactions and 
description of dynamic associations has been co-IP Western blot (1).  In most cases, 
this results in a limited view of the biophysical processes taking place as the co-IP 
Western assays are inherently binary in nature.  Thus, a complex like that of ASK1, 
which is composed of several different proteins, will only be analyzed in a pair-wise 
fashion  (ASK1 and one other protein) for any given stimulus or cellular context.  After a 
series of these studies have been conducted in the literature, a more complete picture 
of the potential behavior of the entire complex will begin to be assembled.   
This is how the ASK1 field has developed and why the current view of the ASK1 
signalosome is that of a consensus two-state system with many different protein-protein 
interactions that all dynamically shift in association with ASK1 upon treatment (2-4).  
The inherent assumption with this type of analysis is that the individual studies are 
cumulative and that the unmeasured components of the signalosome behave similarly 
between analyses.  This assumption is not necessarily true.  In order to truly understand 
how a multiprotein complex is responding to any given stimulus or circumstance, all 
components of the complex must be observed concurrently.  For most complexes, an 
“all-components” view is not possible via Western blot methodologies.  Other major 
shortcomings for immunoassays include relatively poor quantitative characteristics and 
reliance on poorly characterized antibodies. 
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The increased speed and high mass accuracy of modern instruments has 
resulted in an increased use of affinity purification coupled with mass spectrometry to 
analyze multiple proteins in a complex concurrently (5-9).  This advance addresses 
many of the issues inherent to Western blot-based studies but still has a few 
weaknesses.  Typically, AP-MS studies are performed with shotgun MS techniques that 
are good for defining complex membership and can give some evidence for dynamic 
shifts in protein associations with the complex (10, 11).  However, the quantitative data 
from shotgun methods is typically limited by a large degree of missing values from the 
inherent stochastic nature of peptide selection based on signal intensity, which 
undersamples some sequences.  Additionally, protein associations with low 
stoichiometry may not be captured by shotgun analyses due to thresholding effects and 
dynamic range limitations in the method (12). 
 
Technical and conceptual advances in ASK1 complex understanding 
In the studies presented in chapter II, I developed a targeted PRM method for 
precisely monitoring ASK1 protein interaction changes in response to treatment.  The 
information presented in that chapter dealt specifically with the dynamics of the ASK1 
complex in response to HNE treatment, but the method is generalizable to any 
multiprotein complex perturbed by any stimulus.  By utilizing the superior quantitative 
aspects of a targeted MS assay, I bypassed the missing value limitations inherent in 
shotgun MS quantitation and was able to more confidently assay the protein-protein 
interactions with ASK1 across different treatment conditions.  Additionally, because of 
the high throughput capabilities of the PRM assay on a Q Exactive mass spectrometer, I 
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was able to target all known components of the ASK1 multiprotein complex concurrently 
to generate the first “all-components” view of this important stress-transducing system.  
As a step toward an even more quantitative understanding of the ASK1 complex 
protein-protein interaction dynamics, I performed stable isotope dilution assays for many 
of the complex members in order to generate the first ever stoichiometric estimate of the 
composition of this complex. 
The end result of these assays was the identification of several proteins that 
demonstrated concurrent dynamic shifts in association with ASK1 in response to HNE 
treatment.  This was the first time that protein-protein interactions with ASK1 have been 
studied in response to activation by electrophile stress.  Additionally, the SID assays 
allowed me to determine the composition of a minimal ASK1 complex consisting of 
ASK1, ASK2, and 14-3-3 family proteins that were present in a ratio of 2:2:1 
respectively.  This complex composition is supported by not only the SID assays, but 
the distribution of ASK1 in size exclusion experiments.  This minimal complex 
composition coupled with the dynamic rearrangements noted under conditions of HNE 
stress activation generated a new image of how the ASK1 complex operates.  Rather 
than a consensus two-state super-complex composed of many different proteins, as has 
been presented in the literature (3, 4), my data supports the idea of many different 
ASK1 complexes present concurrently in the cell – all as variations of a core complex 
composed of ASK1, ASK2, and a 14-3-3 protein – that transiently associates with other 
reported ASK1-interacting proteins in order to carry out necessary signaling functions in 
response to stress. 
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The use of PRM assays coupled with SID-based measurements of multiprotein 
complex constituents has broader implications than just a better understanding of how 
the ASK1 signalosome functions.  Most of the previously described multiprotein 
complex dynamics in the literature were investigated through the use of immunoassays 
or reconstituted complexes.  As discussed above, the dynamic data obtained from IP-
Western assays is inherently binary, limited in quantitative capacity, and requires high 
quality antibodies for each protein component of the complex.  The information from 
reconstitution experiments has helped to define the behavior of several complexes, but 
this type of assay is difficult to perform.  In many cases, a reconstituted complex may 
not be possible because of the number of proteins involved.  By utilizing targeted PRM 
assays with SID quantitation, all of these limitations are avoided and high quality 
dynamic data can be obtained for almost any multiprotein complex. 
 
ASK1 phosphorylation and stress sensing 
 
Current practices and understanding in the ASK1 field 
 ASK1 can translate the chemical properties of different chemotypes (e.g., 
oxidants, electrophiles) into a single stress response pathway (3, 13-25).  Until now, no 
investigation of how this single sensor protein is able to detect many molecules of 
different chemotypes has been carried out.  It is therefore unknown whether ASK1 
senses all of these stressors via the same mechanism or if each stressor is detected 
through a different means.   
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ASK1 is reported to be phosphorylated on at least 29 residues, and 5 of these 
have been previously identified as dynamic, with phosphorylation states that change in 
response to treatment with oxidants.  All 5 of these residues were discovered through 
mutational analysis and antibodies were generated to track the phosphorylation status 
in response to stress (26-32).  While mutational analysis and phospho-specific antibody 
generation is an established method for describing dynamic phosphorylation sites, it is 
relatively inefficient and time- and labor-intensive.   
Shotgun proteomics has become the method of choice in recent years for 
discovering phosphosites on proteins in an unbiased fashion.  This methodology has 
been tangentially applied to ASK1, as multiple phosphorylation sites have been reported 
through global shotgun analyses in several different contexts that were not focused on 
the ASK1 system.  None of these reported sites have been investigated further to 
determine if they are dynamic in response to stress signaling.  Recently, advances in 
MS technology have enabled the use of targeted MS techniques to track 
phosphorylation status in signaling network proteins (33).   
   
Technical and conceptual advances in ASK1 stress sensing 
 In chapter III, I began to address the question of how ASK1 is able to integrate 
chemicals with different chemotypes into a single pathway response by comparing the 
effect of HNE and H2O2 treatment on the phosphorylation status of ASK1.  This was the 
first comparative study of the phosphorylation state of ASK1 in response to activation by 
two chemically distinct molecules and is the first study to suggest that ASK1 possesses 
different sensing mechanisms for different chemical species.  I utilized shotgun MS for 
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the unbiased discovery of phosphorylation sites on ASK1 in response to both of these 
treatments.  This was the first time that discovery proteomics was performed specifically 
on ASK1 for the purpose of phosphosite identification.  I identified several phosphosites, 
both previously known and novel, that exhibited dynamic responses to stress activation.  
For each stressor used, I detected a unique set of phosphorylated residues, which 
suggested that ASK1 was able to respond to H2O2 and HNE via different mechanisms.  
Interestingly, I also detected a core set of phosphorylations that were shared between 
the two stressors and which exhibited consistent dynamic changes for both HNE and 
H2O2.  This suggested that ASK1 sensed each of these two molecules via a different 
mechanism but was capable of integrating these two signals into a common activation 
of the pathway. 
 In this study, I utilized targeted PRM assays to track the dynamics of the 
identified phosphorylation sites in response to treatment.  This technique allowed me to 
determine which sites were dynamic without the need to perform any mutations or 
generate any antibodies.  Thus, this study can serve as a proof of concept for the use of 
targeted MS assays for the assessment of phosphosite dynamics in general.  It is 
unlikely that MS assays will ever completely replace mutational studies or antibody 
generation, but targeted MS assays can serve as an initial step to narrow down the list 
of potential sites for further assay development via more traditional means. 
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Conclusions and future directions 
 
 The studies presented here have enhanced understanding of two unanswered 
questions in the ASK1 field.  First, I have shown that the ASK1 signalosome is likely not 
a two-state system as it has been conceived of in the literature.  Instead, my data 
supports the idea of a core ASK1 complex that transiently associates with additional 
proteins as needed, with the functional outcome being the concurrent presence of 
multiple different ASK1 complexes in the cell.  However, the studies that support this 
idea of a core ASK1 complex were all performed with HNE as the stress signal 
activating ASK1.  Because of this, it is possible that the two different models of the 
ASK1 signalosome are not in fact mutually exclusive.  It is possible that the way in 
which the ASK1 signalosome functions is dependent on stress activation context.  
Additional experiments examining not only HNE and H2O2, but also several of the other 
known ASK1-activating molecules need to be performed to test this hypothesis. 
 The second question in the ASK1 field that my work began to answer is whether 
or not ASK1 senses different stressors via the same mechanism.  Through the analysis 
of the phosphorylation state of ASK1 in response to two chemically distinct stressors, I 
have shown that ASK1 is likely capable of sensing each through different mechanisms, 
but that both of these sensing mechanisms are capable of activating the ASK1 pathway 
through a common set of phosphorylations on ASK1.  This idea of different stress 
sensing mechanisms present in ASK1 brings up a new major question of how this 
sensing works mechanistically.  In order to understand how the differential 
phosphorylations identified in chapter III allow ASK1 to detect different stressors, a 
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structural biology based investigation needs to be undertaken.  By examining the crystal 
structure of ASK1 as it is activated via different chemical stressors, the role of the 
individual phosphosites in stress sensing may become clear.  In addition to these 
studies, further examination of ASK1 phosphorylation in response to activation by some 
of the other known ASK1-activating molecules should be performed in order to better 
understand how specifically ASK1 is able to sense distinct stressors.  In the studies that 
I performed, ASK1 exhibited two distinct stress sensing mechanisms, but it is unclear if 
there are others.  Given the large number of phosphorylatable residues in ASK1, it is 
likely that there will be several other distinct stress sensing mechanisms present in 
ASK1. 
Both of the questions in the ASK field discussed above were answered through 
the use of discovery and targeted MS proteomics.  This series of studies has 
demonstrated the value of targeted proteomics for analysis of dynamic processes, both 
in the case of multiprotein complex analysis and phosphoproteomic analysis, and I 
predict that this technique will become the new gold standard for these fields. 
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                                        Data to Chapter II:
ASSEMBLY DYNAMICS AND STOICHIOMTERY OF THE APOPTOSIS
SIGNAL-REGULATING KINASE (ASK) SIGNALOSOME IN RESPONSE 
TO ELECTROPHILE STRESS 
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Figure A-1.  ICC images of the three ASK proteins.  ICC results showing proper localization 
of the three ASK proteins with no evidence of aberrant aggregation. 
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Figure A-2.  Dose- and time-dependent activation of the ASK1 MAPK pathway.  (A) ASK1-
TAG cells were treated with increasing concentrations of HNE for 1hr.  Activation of ASK1 was 
observed at all concentrations of HNE used (compare to EtOH) and maximal activation of the 
downstream kinase JNK and p38 was seen at 50mM.  (B) ASK1-TAG cells were treated with 
50mM HNE for the times indicated.  Activation of ASK1 was detected at all time points but 
activation of the downstream kinases was strongest at 1-2hrs. 
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Figure A-3.  ASK1-ATAD3A interaction test.  (A) The interaction of ATAD3A and ATAD3B with ASK1 
seen in the over-expressing (ASK1-TAG) cells was confirmed by Co-IP Western.  (B) However, in 
the context of endogenous expression in parental HEK-293 cells (top two panels) and RT-4 cells 
(which have a higher expression of ASK1), ASK1 and ATAD3A did not co-purify (compare lanes 3 
and 5).  Additionally, activation status of ASK1 did not seem to produce an association (compare 
lanes 8 and 10).  In fact, there was a higher level of ATAD3A precipitation with the pre-immune IPs 
than with the ASK1 IPs (compare lanes 2 and 4 with 3 and lanes 7 and 9 with 8). 
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Figure A-4.  ASK1 knockdown IPs.  An si-RNA knockdown of ASK1 was performed in 293 cells.  (A) 
Western blot analysis of cells treated with non-targeting siRNA and ASK1-targeting siRNA shows 
that ASK1 expression was successfully knocked down.  This can be seen at the whole cell lysate 
level (left panel) and the IP level (right panel).  LRP normalized (B) and SID normalized (C) PRM 
analysis of non-targeting and ASK1-targeting siRNA treated cells show the decrease of ASK1 with 
siRNA treatment.  The majority of the interacting proteins showed no difference with the sole 
exceptions of ASK2 and ASK3.  Black bars denote the mean of each replicate and blue connecting 
lines show the si-RNA dependent drop in the effected peptides. 
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Figure A-5.  SID calibration curve data.  Linear regression curves of all 26 SID 
peptides with theoretical concentration on the x-axis and peak area ratio on the y-
axis. 196
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Figure A-6.  HNE EC50 determination.  (A) EC50 values for HNE were found for each 
cell line using a WST assay. (B) ASK1 activation below (5M) and above (20M) the 
EC50 value. 
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Figure A-7. ASK protein purification.  (A) Western- and (B) PRM-based analysis of the amount 
of target protein purified in each cell line for the HNE concentration-response experiment. 
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Figure A-8.  HNE induced dynamic ASK1 complex changes.  All peptides normalized by LRP for 
the (A) ASK1 IPs, (B) ASK2 IPs, (C) ASK3 IPs, (D) ASK1 Endogenous IPs were plotted as 
grouped scatter plots.  The mean value for each condition is depicted as a bar.  A red bar means 
that the peak areas for this condition were enriched over the negative control based on the 
Wilcoxon rank sum test with p<0.05 or detection in at least half of the replicates for a condition 
and no detection in the negative control samples.  Concentration-response trends were tested in 
two ways: (1) the Jonckheere-Terpstra test was applied to detect an ordered trend in peak area – 
the results of this test are listed below the protein name and peptide sequence on each graph and 
(2) A Kruskal-Wallace test with post-hoc Dunn’s analysis was performed – all significant pairwise 
comparisons are listed on the graphs with bars connecting the significantly different conditions. 
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Figure A-9. HNE induced dynamic ASK1 complex changes.  All peptides normalized by SID for 
the (A) ASK1 IPs, (B) ASK2 IPs, (C) ASK3 IPs, (D) ASK1 Endogenous IPs were plotted as 
grouped scatter plots.  The mean value for each condition is depicted as a bar.  A red bar means 
that the peak areas for this condition were enriched over the negative control based on the 
Wilcoxon rank sum test with p<0.05 or detection in at least half of the replicates for a condition 
and no detection in the negative control samples.  Concentration-response trends were tested in 
two ways: (1) the Jonckheere-Terpstra test was applied to detect an ordered trend in peak area – 
the results of this test are listed below the protein name and peptide sequence on each graph and 
(2) A Kruskal-Wallace test with post-hoc Dunn’s analysis was performed – all significant pairwise
comparisons are listed on the graphs with bars connecting the significantly different conditions.
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Figure A-10.  Enrichment of dynamic ASK1-interacting proteins in HEK-293 cells.  
The 14 proteins that were identified as dynamic interactors in the ASK1-TAG cell line 
were examined in the context of ASK1 endogenous expression to determine if they 
were enriched in the ASK1 IPs compared to the negative control IPs.  ND = not 
detected. 271
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SEC Buffer 50mM HEPES pH 7.5 
10mM KCl 
150mM NaCl 
1mM EDTA 
1mM EGTA 
1.5mM MgCl2 
10% glycerol 
0.1% CHAPS 
0.01% Brij35 
50mM HEPES-KOH pH 7.5 
10mM KCl 
150mM NaCl 
1mM EDTA 
1mM EGTA 
1.5mM MgCl2 
10% glycerol 
0.1% CHAPS 
0.01% Brij35 
Lysis method 5x107 cells/mL were lysed 
with a glass Dounce 
homogenizer in SEC buffer 
supplemented with 1mM 
DTT, and 1X Halt Protease & 
Phosphatase inhibitor. 
5x107 cells/mL were lysed 
with a glass Dounce 
homogenizer in SEC buffer 
supplemented with 1mM 
DTT, 1mM 
phenymethylsulfonyl fluoride, 
and 5 ug/mL aprotinin. 
Spin processing The lysate was centrifuged at 
20,000g for 30 minutes for 
clarification prior to SEC.  
The resulting supernatant 
was frozen at -80oC 
The lysate was centrifuged at 
10,000g for 10 minutes.  The 
resulting supernatant was 
further centrifuged at 
105,000g for 90 minutes.  
This supernatant was frozen 
at -135oC. 
SEC method The stored lysate was loaded 
onto a Superose6 10/300 GL 
column pre-equilibrated with 
the SEC buffer.  Proteins 
were eluted isocratically at 
0.3mL/min and collected in 
0.6mL fractions. 
The stored lysate was loaded 
onto a Superose6 10/300 GL 
column pre-equilibrated with 
the SEC buffer.  Proteins 
were eluted isocratically at 
0.3mL/min and collected in 
0.5mL fractions. 
Protein isolation ASK signalosome complexes 
were isolated via 
immunopurification with anti-
HA beads. 
Each fraction was 
precipitated using 
acetone/ethanol (1:4) 
Amount used for 
subsequent assays 
Samples from 2 column runs 
were used for Western 
analysis.  Samples from 6 
column runs were used for 
PRM analysis. 
Samples from 1 or 4 column 
runs were pooled and 
analyzed by Western 
Size Exclusion Chromatography methods 
Figure A-11.  Size-exclusion fractionation of intact ASK1 complexes.  (A) Methods comparison 
for the SEC assays performed in this study and Noguchi et. al. (B & C) Treatment of ASK1-
TAG cells with ethanol (B) and 50mM HNE (C) yields similar distributions of ASK1 complexes 
with no shift to a higher molecular weight observed upon activation by HNE.  (D) LRP-PRM 
analyses of ASK1, ASK2, and ASK3 in the SEC fractionated samples confirm the western 
results and show no change in complex localization upon activation by HNE. 
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Figure A-11. 
B 
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APPENDIX B 
 
 
 
Data to Chapter III: 
 
 
 
DYNAMIC PHOSPHORYLATION OF APOPTOSIS SIGNAL REGULATING KINASE 1 
(ASK1) IN RESPONSE TO OXIDATION AND ELECTROPHILIC ADDUCTION 
 
275
Figure B-1.  Annotated MS/MS spectra for each putative phosphopeptide.  Where 
possible, the phosphorylation was localized to a single residue.  When this was not 
possible with the data at hand, the phosphorylation was localized to the fewest 
possible sites with sufficient explanatory evidence.  Each page lists the peptide 
sequence, site(s) of modification, MS1 isolation window, precursor mass accuracy, 
annotated MS/MS spectrum, and a table summarizing the identified peaks for the 
MS/MS spectrum. 
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79GRGS[79.96633]SVGGGSR89 
Ser 82/83 
 
Precursor m/z: 528.7345 
Precursor mass error: 5.20 ppm 
 
Isolation window 
Figure B-1. 
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79GRGSS[79.96633]VGGGSRR90 
Ser 82/83 
 
Precursor m/z: 404.8588 
Precursor mass error:  -2.06 ppm 
 
Isolation window 
Figure B-1. 
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81GS[79.96633]SVGGGSR89 
Ser 82/83 
 
Precursor m/z: 422.1718 
Precursor mass error: -0.83 ppm 
 
Isolation window 
Figure B-1. 
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81GS[79.96633]SVGGGSRR90 
Ser 82/83 
 
Precursor m/z: 500.2227 
Precursor mass error: -1.40 ppm 
 
Isolation window 
Figure B-1. 
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135LDFGET[79.96633]TVLDR145 
Thr 140/141 
 
Precursor m/z: 673.3052 
Precursor mass error: 0.30 ppm 
 
Isolation window 
Figure B-1. 
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263VAQASS[79.96633]SQYFR273 
Ser 268/269 
 
Precursor m/z: 662.2910 
Precursor mass error: -1.36 ppm 
 
Isolation window 
Figure B-1. 
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353FHY[79.96633]AFALNR361 
Tyr 355 
 
Precursor m/z: 609.7716  
Precursor mass error:  7.87 ppm 
 
Isolation window 
Figure B-1. 
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944KKKT[79.96633]QPKLSALSAGSNEYLR963 
Thr 947/S952 
 
Precursor m/z: 575.5613 
Precursor mass error: -0.52 ppm 
 
Isolation window 
Figure B-1. 
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945KKTQPKLS[79.96633]ALSAGSNEYLR963 
Thr 947/S952 
 
Precursor m/z: 543.5375 
Precursor mass error:  -2.85 ppm 
 
Isolation window 
Figure B-1. 
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951LSALS[79.96633]AGSNEYLR963 
Ser 955 
 
Precursor m/z: 730.8403 
Precursor mass error:  3.28 ppm 
 
Isolation window 
Figure B-1. 
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951LSALSAGS[79.96633]NEYLR963 
Ser 958 
 
Precursor m/z: 730.8427 
Precursor mass error:  0 ppm 
 
Isolation window 
Figure B-1. 
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947TQPKLSALSAGS[79.96633]NEYLR963 
Ser 955/958 
 
Precursor m/z: 638.9838 
Precursor mass error:  -2.50 ppm 
 
Isolation window 
Figure B-1. 
288
946KTQPKLSALSAGS[79.96633]NEYLR963 
Ser 955/958 
 
Precursor m/z: 681.6821 
Precursor mass error: -2.30 ppm 
 
Isolation window 
Figure B-1. 
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951LSALSAGS[79.96633]NEYLR963 
Ser 955/958 
 
Precursor m/z: 730.8452 
Precursor mass error: -3.42 ppm 
 
Isolation window 
Figure B-1. 
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1000TRAKS[79.96633]C[57.02146]GERDVK1011 
Thr 1000/S1004 
 
Precursor m/z: 496.2332 
Precursor mass error: -1.21 ppm 
 
Isolation window 
Figure B-1. 
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1000TRAKS[79.96633]C[57.02146]GERDVKGIR1014 
Thr 1000/S1004 
 
Precursor m/z: 453.9788 
Precursor mass error: -1.93 ppm 
 
Isolation window 
Figure B-1. 
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1002AKS[79.96633]C[57.02146]GERDVK1011 
Ser 1004 
 
Precursor m/z: 615.2717 
Precursor mass error:  -1.38 ppm 
 
Isolation window 
Figure B-1. 
293
1057ILT[79.96633]EDQDKIVR1067 
Thr 1059 
 
Precursor m/z: 470.5735 
Precursor mass error: -1.70 ppm 
 
Isolation window 
Figure B-1. 
294
1240S[79.96633]LNVQLGR1247 
Ser 1240 
 
Precursor m/z: 483.7427 
Precursor mass error: -1.34 ppm 
 
Isolation window 
Figure B-1. 
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Figure B-2.  Graphs of all detected and quantified ASK1 phosphopeptides in the HNE 
treated cells.  For each concentration point (10 and 50 mM) the peptide peak are was 
compared against the peptide peak area for the control sample (0 mM).  Graphs are 
shown for  (A) Ser 83 (B) Thr 947|Ser 952 (C) Ser 955|Ser 958 (D) Thr 1000|Ser 
1004 (E) Ser 1059 (F) Ser 1240.  
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Figure B-3.  Graphs of all detected and quantified ASK1 phosphopeptides in the 
H2O2 treated cells.  For each concentration point (500 and 5000 mM) the peptide 
peak are was compared against the peptide peak area for the control sample (0 mM).  
Graphs are shown for  (A) Ser 83 (B) The 140|Thr 141 (C) Ser 268|Ser 269 (D) Tyr 
355 (E) Thr 947|Ser 952 (F) Ser 955 (G) Ser 958 (H) Ser 1004 (I) Ser 1240.  
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Figure B-4.  Annotated MS/MS spectra for each putative HNE adducted ASK1 
peptide. Each page lists the peptide sequence, site of modification, MS1 isolation 
window, precursor mass accuracy, annotated MS/MS spectrum, and a table 
summarizing the identified peaks for the MS/MS spectrum. 
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927AC[158.13068]ANDLLVDEFLK939 
Cys 928 
 
Precursor m/z: 804.93219 
Precursor mass error: 1.14ppm 
 
Isolation window 
Figure B-4. 
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1004SC[158.13068]GERDVK1011 
Cys 1005 
 
Precursor m/z: 526.27618 
Precursor mass error: -0.60ppm 
Isolation window 
Figure B-4. 
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